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Introduction 
Multicellular organisms are exposed to a multitude of microbial and viral pathogens that 
make use of a wide variety of strategies in order to invade the host and escape host 
counterattacks. In the arms race between host and pathogen, the latter has the advantage 
of a much shorter generation time, e.g. less than 30 minutes for E.coli compared with 20 
years for the human host. Consequently, the pathogens can quickly adjust their strategies 
through natural selection. The mammalian immune defence system therefore not only 
faces the problem of having to recognize a large number of different pathogens as foreign, 
but must also be able to reveal variants of pathogens not previously encountered by the 
host in evolution, and to launch the right kind of response, adjusted to type and severity of 
the attack. These requirements have resulted in the development of a flexible and complex 
defence system. A complex and flexible system is prone to malfunction and this may have 
serious consequences for the organism. Malfunctions can be divided into three major 
types: 1) immunodeficiency, or the failure to detect and react to intruders, 2) 
autoimmunity and 3) maladjusted reactions, e.g. allergies.  
 
The focus of this thesis is autoimmunity, a condition where the defence system reacts and 
inflicts tissue damage to the body’s own constituents. Most autoimmune diseases are 
relatively rare, the more common are rheumatoid arthritis (RA), multiple sclerosis (MS), 
systemic lupus erythematosus (SLE), autoimmune thyroid disease and type 1 diabetes. 
Collectively autoimmune diseases constitute the third largest category of illnesses in the 
industrialized world, next only to cardiac disease and cancer. 
 
Autoimmune diseases are complex disorders where several genes and environmental 
factors contribute to disease development. Identification of such risk factors will be 
important for improved disease prophylaxis, diagnosis and therapy. The ultimate goal of 
the work presented is to identify genes associated with human autoimmune diseases and 
find out how they contribute to precipitation of disease. To this end, we have taken 
advantage of an experimental animal model, where autoimmune joint inflammation is 
induced by application of adjuvant oils to the skin. Gene candidates emerging from this 
work have subsequently been tested for association with RA in the human. As a 
background to the work, a brief introduction to the immune system and to methods for 
identifying genetic risk factors will be given. 
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The major arms of the immune system 
Most of our cells contribute to defence against pathogens, the majority acting as a “home 
guard”. In addition we have a set of specialized cells collectively referred to as 
leukocytes, dedicated to immune defence. To distinguish between self and non-self, 
leukocytes are equipped with molecules called antigen receptors. Depending on how 
leukocytes recognize pathogens and the immune reaction launched, the immune system 
can be divided into four major branches as indicated in table 1. 
 
Table 1. The antigen receptors used by the four major arms of the immune system 
 Innate  Adaptive  
Humoral  Soluble lectins 
Complement system 
B-cell receptors 
(antibodies, 
immunoglobelin)  
Cellular NK cell receptors 
Toll like receptors 
T cell receptors  
( and  TCR) 
 
The table shows the types of antigen receptors employed in each arm. In the case of the innate system only a 
couple of examples are given from a much longer list of receptor types. 
 
In the cellular system the antigen receptors remain cell bound, whereas in the humoral 
system the antigen receptors are released into the tissue fluids. The cells of the non-
adaptive immune system respond vigorously upon first encounter with a particular 
antigen. In contrast, when cells of the adaptive system encounter antigen, the primary 
immune response is weak, but is enhanced upon later encounter with the same antigen.  
 
The adaptive immune system 
The hallmarks of the adaptive immune system are specificity and memory. Specificity is 
achieved through the generation of diverse antigen receptors by gene rearrangement. The 
process is independent of antigen and produces an almost infinite number of different 
antigen receptor specificities. The rearrangement of genes occurs at the DNA level, and is 
inherited stably so that all daughter cells from a B or T cell that have successfully 
undergone productive rearrangement will express the same antigen receptor specificity as 
the parental cell. Due to allelic exclusion the cells will as a rule express only one single 
receptor specificity. As a consequence tolerance can be induced at the level of cells by 
deleting clones with self reacting receptors. 
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The clonal division comes at a cost. As the vast majority of the cells never become 
engaged in immune responses, B and T cells have adopted a “resting” phenotype, 
consisting of little more than a condensed nucleus surrounded by a thin brim of 
cytoplasm. Furthermore, the sheer multitude of different clones means that the average 
size of each clone is tiny. Upon recognition of a particular antigen the reactive clones 
therefore first have to expand and the cells subsequently to differentiate into effector cells. 
It will therefore take several days to launch a primary immune response, which 
consequently will be slow and relatively weak. Following proliferation, not all the 
progeny differentiate into effector cells. Some are set aside as memory cells, with the 
same antigen specificity as the parental cells. These memory cells are of greater quantity 
than the parental clone and are more readily activated. Upon later challenges with the 
same antigen, the immune response is faster and stronger, a feature denoted as 
immunological memory. 
 
The low frequency of antigen specific cells restricts the chance of antigen detection of a 
particular microbial intruder. In order to increase the probability of antigen detection, B- 
and T-cell circulate between strategically positioned checkpoints named peripheral 
lymphoid tissues, which include lymph nodes, splenic white pulp, tonsils and intestinal 
Peyer’s patches. To further assist in antigen detection, professional antigen presenting 
cells (APC) capture antigen in the periphery and bring it to the lymphoid tissues where it 
is presented to T cells. In addition, the APC transmits “secondary” signals, mediated by 
cell bound co-receptors and secreted proteins, which contribute to instructing the T cell 
how to respond to the antigen presented. 
 
The receptor repertoire generated through gene rearrangement can in principle bind any 
antigen. An inevitable by-product of this process is the generation of antigen receptors 
directed to self antigens. Because their existence may confer autoimmune reactions, 
tolerance to self constituents needs to be learnt during ontogeny. Due to the one cell-one 
receptor strategy tolerance can be obtained by eliminating or inactivating cells equipped 
with self-reactive receptors from the total receptor repertoire. This method of ontogenetic 
tolerance acquisition is probably the rationale behind the one cell-one receptor strategy, as 
it would be far more difficult to construct systems where cells could obtain the necessary 
feed-back information for differential handling of a multitude of expressed, nearly 
identical receptors. One great advantage with generating receptors against everything and 
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subtracting the self-reactive is that the remaining receptor repertoire should be able to 
bind all kinds of non-self antigens, including antigens previously never encountered in the 
phylogeny of the species. Evidently, this useful property, referred to as anticipation, 
cannot develop within a system dependent on phylogenetic learning. 
 
Once activated, B cells differentiate into plasma cells which produce antibodies with the 
same specificity as the membrane bound antigen receptor, but now in a form secreted into 
the tissue fluids where they bind extracellular antigen. The binding elicits a variety of 
effector mechanisms, such as ingestion by phagocytic cells or the activation of the 
complement system, both leading to clearance of the antigen. Binding of antibodies may 
also neutralize invading pathogens, by immobilizing and hindering them from entering 
cells. Activated cytotoxic T cells, on the other hand, target infected cells and kill them by 
direct contact. Normally, the activation of B cells and cytotoxic T cells requires the 
assistance of helper T cells, provided by physical cell-to-cell contact and by secreted 
cytokines. In order to provide the required stimulatory signals, the helper T cells need to 
be activated through interaction by professional APC. As indicated above, this depends 
both on the recognition of antigen presented by the APC and the reception of secondary 
signals. Importantly, the helper T cells recognize different antigen determinants than the 
B cells and the cytotoxic T cells do. The requirement of independent recognition of 
different antigen epitopes plus stimulation by secondary, co-stimulatory signals represents 
an important safe-guard against inappropriate activation of immune responses.    
 
The non-adaptive (innate) immune system 
The de novo generation of novel protein-encoding genes through gene rearrangement 
during ontogenetic development of the individual is a unique property of the adaptive 
immune system. In contrast, the receptors used for antigen recognition by the leukocytes 
belonging to the non-adaptive or innate arm of the immune system are inherited in the 
traditional way, i.e. “hard-wired” via the germ-line DNA. This raises the question of how 
to avoid the problem referred to above with rapidly proliferating parasites escaping 
detection through natural selection. The answer is that microbes contain macromolecular 
structures that are hard if not impossible to alter without strongly reducing the fitness of 
the microbe, thus prohibiting escape by the microbe from immune detection by mutations. 
Examples are the complex peptidoglycan bacterial coat and the formyl group attached to 
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the initial methionine in all newly synthesized bacterial proteins. The germ-line encoded 
receptors of the innate immune system are directed against such evolutionary conserved 
molecular motifs. Evolutionary conservation means that these structures often are shared 
by a range of different microbes. They are therefore referred to as pathogen associated 
molecular patterns (PAMP) (1). Immune receptors recognizing PAMPs are called pattern 
recognition receptors (PRR) and include Toll like receptors (TLR), intracellular Nod-like 
receptors and C-type lectin-like receptors (CTLR, i.e. containing C-type lectin-like 
domains) (1-3). Extracellular plasma bound TLR detect components of the cell wall of 
bacteria, fungi and protozoa, whereas intracellular TLR can detect bacterial and viral 
nucleic acid structures. Upon recognition of pathogens, TLR have the ability to initiate 
intracellular signalling leading to activation of the cell (4). Many, but not all CTLR bind 
carbohydrates. Some CTLR contain an internalization motif and are internalized upon 
binding with antigen, resulting in antigen presentation. However, a number of CTLR 
possess signalling motifs and are involved in intracellular signalling similar to the TLR 
(5). Binding of PRR to pathogens or pathogen derived structures will activate host 
defence mechanisms such as secretion of inflammatory cytokines and chemokines as well 
as internalization or lysis of the microbe.  
 
With receptor specificities completely defined by the germ-line DNA, self-tolerization is 
acquired phylogenetically through natural selection. There is therefore no need for 
tolerance acquisition ontogenetically, i.e. for the individual to “learn” the difference 
between self and non-self, and therefore no need for clonal division of the cells with 
respect to antigen receptor specificities. Each cell may therefore simultaneously carry 
many different antigen receptors, enabling them to recognize a wide range of different 
pathogens. Following intrusion of antigens, a substantial fraction, if not the majority of 
these cells will immediately recognize the intruder. Rather than being assigned to tedious, 
most of the time non-productive patrolling of control posts, like the B and T cells have to 
do, the cells of the innate system can therefore be directly positioned at the frontlines 
where the enemy is likely to attack, i.e. along the skin and the mucosal linings and in the 
bloodstream. Moreover, upon encounter with intruders the cells do not need to undergo 
rounds of proliferation to amplify the response and subsequent maturation and, but are 
combat-ready, pre-packed with various granules containing antimicrobial proteins, 
lysosomal enzymes and regulatory cytokines. This arm of the immune system is therefore 
acting fast even on the first encounter with antigen, hence the term “innate”, but the 
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response is not amplified in subsequent encounter with the same antigen, hence the term 
“non-adaptive”. 
 
Another innate response is the complement system which consists of a number of secreted 
proteins that interact with each other forming a cascade. The proteins are circulating in the 
blood, and upon binding to microbes the cascade is set off, cleaving the next protein in the 
cascade. Some of the peptides generated in the cascade act as inflammatory agents 
attracting phagocytic cells (neutrophils and macrophages), others create an attack 
complex in the target cell membrane, leading to cell lysis, or mark the targets for uptake 
by phagocytes (opsonization). 
 
In addition to constituting an independent arm of the immune defence system, able to 
combat intruders on their own, the innate system provides support and instruction to the 
cells of the adaptive immune system. Of particular importance is the key role played by 
professional APC in stimulating helper T cells. As briefly mentioned above, professional 
APC sample, process, transport and present antigens to T cells, and through the 
expression of co-stimulatory receptors and secreted cytokines deviates the immune 
responses in suitable directions, adjusted to the type of attack. As will be detailed below, 
this includes deviation towards non-response. 
 
Lectin receptors  
The professional APC utilize a wide array of receptors and co-receptors to recognize and 
sample foreign antigens and to communicate via cell-to-cell contact with other immune 
cells. For reasons explained below, we shall here concentrate on one subset of such 
receptors, belonging to the C-type lectin superfamily. The C-type lectin-like receptors 
constitute one subgroup of a large class of proteins collectively referred to as lectins, 
which originally are defined as carbohydrate binding proteins. The CTLR are 
characterized by the possession of one or more C-type lectin-like domains, consisting of a 
characteristic structural motif first identified as the carbohydrate recognition domain of 
mannose binding lectin, where the C denotes calcium dependent binding of carbohydrates 
(6). Many of the proteins with this domain do not depend on calcium for saccharide 
binding or do not even bind carbohydrates at all, hence the term “lectin-like”. In 
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vertebrates the C-type lectin-like domains are classified into 17 groups based on overall 
protein architecture (6-8).  
 
 
 
 
 
 
 
 
 
 
 
Fig. 1 C-type lectins and the C-type lectin domain 
Some of the groups in the C-type lectin superfamily, including group II and group V, and diagrammatically 
the carbohydrate recognition domain (C-type lectin domain) of mannose binding protein, with alpha helices 
in green, beta strands in red, Ca++   -binding sites in yellow and position of saccharide binding site indicated 
by blue hexagon. From Kurt Drickamer: www.imperial.ac.uk/research/animallectins/  
 
Group II and V contain membrane bound C-type lectin-like receptors of which many are 
expressed by leukocytes and may function as PRR. Group II and V are type 2 
transmembrane (TM) proteins with a single membrane external C-type lectin domain (6). 
The group V receptors are mainly encoded by genes in the Natural Killer gene complex, 
NKC, and the receptors are referred to as killer cell lectin-like receptors, KLR. The KLRs 
are expressed as disulphide linked homo- or heterodimers (9,10). The characteristic amino 
acid motif mediating Ca2+ dependent carbohydrate binding has been lost, and in cases 
where ligands have been identified most of these are proteins (9,11). A notable exception 
is Dectin-1, where the ligand is a -glucan (12). Many of the receptors contain known 
signalling motifs and are involved in regulation of NK cell activation. The signalling 
properties of the KLRs will be detailed below. 
 
In contrast to the group V receptors, the group II receptors have retained their motifs for 
carbohydrate and Ca2+ binding, and carbohydrate ligands have been identified for many of 
the receptors (8,13,14). Many of the receptors contain distinct internalization motifs in the 
cytoplasmic tails indicating that these receptors are involved in pathogen internalization 
(15). One subgroup of the group II receptors are the receptors encoded by genes in the 
antigen presenting cell lectin-like receptor gene complex, APLEC. The APLEC receptors 
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(APLRs) do not contain known internalization motifs; however some of the receptors 
contain signalling motifs similar to the KLRs and are probably involved in regulation of 
cell activation (16-19). The role of the APLRs will be discussed in more detail in the 
general discussion. 
 
Signalling in C-type lectin receptors 
The focus of this thesis is the APLEC receptors. Some of these contain signalling motifs 
identical to those present in KLR. As most studies have been performed on KLR, their 
signalling properties will be outlined as a likely model of APLR functional properties.  
 
The KLR come in two functional forms, activating and inhibitory. The inhibitory 
receptors have intracellular domains with the immunoreceptor tyrosine-based inhibitory 
motif (ITIM) V/I/LxYxxL/V (where x denotes any amino acid). Upon binding of ligand, 
the ITIM tyrosine becomes phosphorylated, followed by recruitment and activation of 
SH-2 domain-containing tyrosine phosphatases that mediate the downstream effect, 
inhibition of the killer cell (20,21). In contrast, the activating receptors do not contain any 
known intracellular signalling motif. As a rule, they instead contain a positively charged 
amino acid in their TM domain. The positive charge facilitates association with TM 
adapter proteins containing a negatively charged amino acid in their TM domain (fig 2). 
The adapter proteins Dap12 and FcR contain the immunoreceptor tyrosine-based 
activation motif (ITAM) YxxL/Ix6-8YxxL/I in the cytoplasmic domain, whereas Dap10 
contains a YINM motif. Upon receptor ligation the tyrosine becomes phosphorylated, 
recruiting tyrosine kinases which trigger an activating signalling pathway (21). Several of 
the genes in the NKC encode protein chains lacking signalling motifs. Some of these form 
heterodimers with chains containing such motifs. This is the case for human CD94, which 
associates with either the inhibitory NKG2A chain or the inhibitory NKG2C chain and for 
rat KLRE, which associates with either the inhibitory KLRI1 or activating KLRI2 (10,22). 
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Figure 2. Relative positions of charged amino acids in TM domain of adapter proteins 
The adapter proteins DAP10 and DAP 12 contain a negatively charged amino acid in the center of the TM 
domain, whereas FcR contain a negatively charged amino acid close to the extracellular border of the TM 
domain. For association, the receptors need an amino acid with a positive charge in the corresponding 
position. The numbers indicate the position of the charged residue counted from the extracellular surface 
(adapted from (23)). 
 
The expression of receptors with opposing signalling function reflects complex 
mechanisms for regulation of cell activation, where the signals mediated by the receptors 
are integrated and the cellular activation status depends on the balance between activating 
and inhibitory signals.  
 
Antigen presentation  
Antigens are presented to T cells by specialized molecules on the cell surface. These 
molecules are encoded by genes residing in the Major Histocompatibility Complex, 
MHC. The human MHC, localized on chromosome 6, is the most gene dense genomic 
region known and the majority of the genes within this complex encode proteins with 
immunological functions. The proteins can be divided into three classes termed MHC 
class I, II and III, where the classical MHC class I and MHC class II genes encode 
proteins that present peptides to the T cells. There are several different MHC class I and 
class II loci, most of which are highly polymorphic (24). The classical class I molecules 
presents peptides derived from proteins within the cell, either a self constituent or derived 
from an intracellular pathogen. The MHC class I molecules present peptides to cytotoxic 
T cells. The majority of nucleated cells express MHC class I molecules, and can thus be 
screened for intracellular parasites. If a cytotoxic T cell recognizes the peptide-MHC class 
I complex, it can kill the cell once activated (24).  
 
 18
Peptides presented by MHC class II molecules are derived from exogenous proteins 
engulfed by the cell either by phagocytosis or by receptor mediated endocytosis. The 
proteins are broken down into peptides in endosomes and lysosomes and loaded onto 
MHC class II molecules. The complex of MHC class II molecules and peptide is then 
brought to the cell surface and is presented to helper T cells. MHC class II molecules are 
constitutively expressed by professional antigen presenting cells which include 
macrophages, B-cells and dendritic cells (25). 
 
Dendritic cell 
Among the professional antigen presenting cells dendritic cells (DC) are unique in their 
ability to activate naïve helper T cells. The cells constitute a heterogenous group of cells. 
Two different lineages, lymphoid and myeloid have been described, and the different 
lineages can be divided in different subsets and maturation stages with different 
phenotypes, localizations and functions. As the DC phenotypes depend on lineage and 
maturation stage, only a general overview of dendritic cells will be given here.  
 
The DC typically resides in tissues in an immature state. The distribution of immature DC 
is especially high in the skin and along the mucosal linings, the entry point of the 
microbes. Immature DC has low MHC class II expression and high PRR expression. 
Upon recognition of pathogen, the DC internalizes the pathogen and undergoes 
phenotypic alterations referred to as maturation, characterized by antigen processing and 
up- and down-regulation of receptors. The cell is mobilized, leaving the peripheral tissue. 
The exit route is mainly with draining lymph, and with the chemokine receptor CCR7 (a 
lymph node homing receptor) up-regulated, the cell is usually destined to end up in the 
draining lymph node. MHC class II molecules are translocated to the plasma membrane 
and co-stimulatory molecules and secretion of cytokines are up-regulated. The capacity to 
phagocytose is diminished during maturation. Upon arrival in the lymph node, the by now 
mature DCs are ready to present antigen to naïve T cells (26-28).  
 
Upon pathogen recognition DC also secrete various cytokines in the infected tissue. The 
cytokines serve to stimulate tissue resident macrophages and to attract blood-borne NK 
cells and neutrophils. These are immediately engaged in local battle against the intruders 
while they at the same time recruit precursor DC. The precursor DC subsequently 
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develops into immature DC, replacing the recently emigrated DC. As long as pathogens 
are present, maturing DC will continue to migrate to the draining lymph node, sustaining 
the activation of T cells. Thus dendritic cells are important to activate and amplify both 
the innate and the adaptive response (27,28). In addition, DC plays a crucial role in both 
central and peripheral tolerance induction.   
 
Tolerance  
The receptor repertoire generated through gene rearrangement can in principle bind any 
antigen, including self antigens. The presence of clones with self-reacting receptors may 
lead to autoimmune reactions, and tolerance to self constituents needs to be learnt. Both 
B- and T cells need to be tolerized, but here only the mechanisms for T cell tolerance will 
be described. Generally the helper T cell is the crucial cell to tolerize, as both B cells and 
cytotoxic T cells need assistance from helper T cells for activation. In the thymus the 
developing T cells, or thymocytes, are educated, i.e. they undergo positive and negative 
selection, so that non-functional clones are selected away and self-reacting clones deleted. 
The outcome is a pool of T cells capable of recognizing foreign antigen presented by self- 
MHC molecules. The deletion of self-reactive T cell clones during thymocyte 
development is referred to as central tolerance. The process, however, does not 
completely eliminate all potentially self-reactive T cells. Autoagressive T cells escaping 
the thymus are instead rendered unresponsive by control mechanisms referred to as 
peripheral tolerance.  
 
Central tolerance 
For their continued survival developing thymocytes depend on signals mediated through 
their T cell receptor (TCR) and thus on the ability of their TCR to bind self peptide-self 
MHC complexes and the strength of this binding (29). Thymocytes with a TCR that do 
not bind self MHC are useless, as they will not be able to interact with infected target 
cells or APC in the periphery. If the TCR is non-functional, no signal will be transmitted 
and the thymocytes are eliminated due to lack of stimulation - “death by neglect”. 
Conversely, thymocytes carrying a TCR with strong affinity for self peptide-MHC 
complex are potentially dangerous. High affinity TCRs mediate strong signals which 
induce apoptosis and thus eliminate the thymocyte by negative selection. Thymocytes 
with low TCR affinity for self peptide-MHC complex are unlikely to react with self in the 
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periphery; however, they may potentially bind strongly to non-self peptide presented by 
self MHC. The intermediate signalling through low affinity TCR will give a sufficiently 
strong signal for survival, but not so strong as to induce apoptosis. These cells are 
consequently positively selected for further differentiation into mature T cells (30,31). 
The signalling strength is not dependent on TCR affinity alone, but also on overall avidity 
of receptors, co-receptors and co-stimulatory molecules (29,32). 
 
A requirement for central tolerance induction is the presentation of a diverse array of 
tissue-restricted antigens (TRA) in the thymus. A population of epithelial cells in the 
thymic medulla, mTEC are specialized to express a diverse set of non-thymic, tissue-
specific molecules. This promiscuous expression of self-antigens represents virtually all 
organs, thereby mirroring the peripheral self (33). The expression of TRA in mTEC is in 
part controlled by a transcription factor called AIRE (autoimmune regulator) 
predominantly expressed in the mTEC (34,35). As the name imply AIRE is involved in 
the regulation of autoimmune disorders. Mutations in the human AIRE gene cause a 
multi-systemic autoimmune syndrome known as autoimmune polyendocrinopathy-
candidiasis-ectodermal dystrophy (APECED) (36,37). Aire knock-out mice suffer from 
autoimmune symptoms that affect multiple organs similar to the human syndrome 
APECED and analysis of mTEC from Aire -deficient mice showed reduced transcription 
of several tissue-specific genes associated with various autoimmune diseases (34,38). The 
transcription level of a number of TRA appears to be dependent on Aire to various 
degrees, indicating complex regulation of expression by Aire. Moreover, additional 
factors that regulate TRA expression exists as transcription of some genes are not 
influenced by Aire at all (34,39-41). 
 
The presentation of TRA to thymocytes may be mediated by mTECs, or by thymic APC. 
It has been shown that TRAs expressed in mTECs can be transferred to and cross-
presented by thymic DCs (42). Transfer may be a result of antigen uptake of secreted 
exosomes or uptake of apoptotic bodies of mTECs (43,44). In addition to regulating TRA 
expression, Aire induces apoptosis in mTECs, a possible mechanism to promote cross-
presentation of TRA by thymic DC (31,45). 
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Peripheral tolerance 
Despite the clonal deletion of autoreactive T cell clones during thymocyte development, 
some autoreactive T cell clones escape to the periphery. However, several peripheral 
mechanisms contribute to keeping these potentially dangerous cells in check. Self 
antigens are constantly taken up and processed by immature DC and presented to T cells 
in the draining lymph node. Immature DC have low levels of MHC class II molecules and 
costimulatory receptors (46). If an autoreactive T cell recognise self antigen presented by 
immature DC, the T cell will not receive appropriate signals to be activated. The 
engagement of TCR but lack of other activation signals will result in apoptosis of the T 
cell. This is a similar mechanism to negative selection in thymus and is called peripheral 
clonal deletion. In a few cases the cell is not deleted, but rendered unresponsive, a state 
referred to as T cell anergy. Upon later encounter with the antigen anergized T cells 
cannot be activated even when the proper co-stimulatory signals are present (47).  
 
Furthermore, many self components are so scarce that the antigens are rarely presented by 
DC, and the chance of being detected by a T cell is minute. Because the antigens are 
present, but do not engage TCR and provoke a response, the immune system is said to 
ignore these antigens. Some self antigens are never detected by T cells because they only 
exist in certain anatomical sites called immunologically privileged sites. Main examples 
are the anterior chamber of the eye, the testis and the central nervous system. Even 
foreign antigens accessing these sites do not trigger an immune response. The privileged 
sites are usually protected by a barrier reducing infiltration of cells and large molecules. 
Furthermore, some cells in privileged sites express Fas ligand (FasL), which can bind Fas 
receptor on T cells. The ligation of Fas and FasL induce apoptosis of the T cell. In 
addition, the privileged sites have minimal lymphatic drainage; few tissue specific 
antigens will drain to lymph nodes to be presented there, resulting in little or no activation 
of T cells (48,49). 
 
Subsets of helper T cells and immune deviation 
Upon interaction with activated antigen-presenting cells such as DC, T helper (Th) cells 
can differentiate into a variety of effector subsets. The T helper cells have traditionally 
been divided in two subsets depending on the cytokine profile and effector functions, first 
described by Mosmann and Coffman in the mid-eighties (50). T helper subset 1 (Th1) 
produce a cytokine profile characterized by the production of interferon- (IFN) and IL-
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2. In general, Th1 responses are protective against infections of intracellular pathogens. In 
contrast, Th2 subset produces IL-4, IL-5, IL-10, and IL-13, promoting protection against 
extracellular parasites, including helminths. The two subsets counter-regulates each other 
as IFN inhibit differentiation of Th2 cells and IL-4 inhibits differentiation of Th1 cells 
(51). The differentiation to either subsets are called polarisation. As a strong Th1 response 
may evoke a chronic inflammation leading to tissue damage and autoimmunity, skewing 
an immune response towards a Th2 response can avoid autoimmunity. A shift in Th1/Th2 
response is called immune deviation and was described as a mechanism of non-deletional 
T cell tolerance (52).  
 
In addition to the classical T helper cell subsets and regulatory T cells, new subsets have 
been proposed, based on distinct cytokine production. Only the subset called Th17, 
however, is generally accepted as a genuine Th subset. Th17 cells secrete the pro-
inflammatory cytokine IL-17A (IL-17). Th17 cells are involved in clearance of pathogens, 
especially at mucosal surfaces, and are also associated with the pathogenesis of 
experimental autoimmune diseases and human autoimmune diseases. Tissues with 
chronic inflammation in Multiple Sclerosis (MS), RA and psoriasis patients are infiltrated 
by a high number of Th17 cells (51,53,54).  
 
It appears that Th1 and Th2 response restrict Th17 polarization, but evidence of the 
opposite is, as of yet, not found. As aberrant Th1 and Th17 responses are associated with 
autoimmunity and Th2 responses with allergy and asthma, the balance between the 
subsets needs to be under tight control. It is now recognized that a population of T cells 
called regulatory T cells plays a major role in the modulation of the Th1, Th2 and Th17 
responses and tolerance induction. 
 
 
Regulatory T cells 
The role of regulatory T cells (Treg) is emerging as perhaps the most important 
mechanism for peripheral tolerance. Tregs are specialized suppressor cells that actively 
suppress the activation, differentiation and proliferation of T cells as well as the effector 
functions of activated T cells. Tregs may also modulate the activity and function of other 
regulatory cells in particular dendritic cells (55,56). Naturally arising Tregs 
(CD4+CD25+foxp3+) are thought to derive from autoreactive thymocyte precursors and 
 23
complete their functional maturation in the thymus. These Tregs are more readily 
activated upon antigen exposure and exert dominant control over naïve T cells in the 
periphery (56). Although Tregs are activated by specific antigen through the TCR, the 
Treg can suppress effector T cells with many other antigen specificities, a feature called 
bystander suppression.  
 
The importance of Treg in tolerance induction is demonstrated in several rodent models. 
Depletion of Treg in rodents leads to spontaneous development of autoimmune diseases 
and the reconstitution of Treg prevents autoimmune symptoms (57-60). Humans with 
mutation in FOXP3, the main transcription factor controlling the development of Treg, 
develop multisystem autoimmune diseases (61). 
 
The mechanisms of Treg suppression are complex and not very well defined. Tregs may 
mediate suppression through direct cell contact with effector T cells by the receptors 
CD39, CD73 and LAG-3 and through production of inhibitory cytokines, in particular IL-
10 and TGF (62). It is also proposed that Tregs can mediate suppression by cytolysis of 
effector T cells by means of granzyme and perforin and by disruption of metabolic 
pathways, i.e adsorbing IL-2 needed for T-cell survival (55,62). Finally Tregs may kill 
DC necessary for T-cell activation, by means of granzyme and perforin or down-modulate 
DC in a CTLA-4 dependent mechanism (62).  
 
Self /non-self and danger signals  
The first postulate of tolerance was made by Burnet in “The production of Antibodies” 
from 1949. To explain the lack of an antibody response in animals exposed to foreign 
antigen during fetal life, as observed by Ray Owen, Burnet proposed that self/non-self 
discrimination is established during embryonic development. He later formulated the 
clonal selection theory, the deletion of self reacting clones of B cells during embryonic 
development. Experimentally induced tolerance was first described in 1953 by Medawar, 
when he demonstrated that tolerance to skin grafts can be induced by inoculation of living 
cells from strain A into foetal mice of the inbred CBA strain (63). In 1960 Burnet and 
Medawar were jointly awarded the Noble prize in medicine and physiology for their 
discovery of tolerance. To date the concept of tolerance largely builds on the clonal 
selection of B and T cells, although some modifications have been made, i.e tolerance is 
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not induced during embryonic development only, but rather during thymocyte and B cell 
development. 
 
The role of central tolerance for the body's ability to distinguish between self and non-self 
has been challenged by several immunologists. The most prominent alternative theory is 
the “danger model” championed by Polly Matzinger. The danger model proposes that 
distressed or injured cells release danger signals, and these danger signals can be detected 
by various PRR leading to activation of the APC and initiation of an innate response. 
Activated APC (DC in particular) will secrete activating cytokines and up-regulate co-
stimulatory molecules, facilitating the activation of helper T cells. In the absence of 
danger signals APC will not be activated and will fail to activate helper T cells, auto-
reactive or not, thus sustaining functional tolerance. Healthy tissues, free of injury or 
infection and accordingly danger signals, may constantly induce tolerance to self antigens 
in this way (64). 
 
Cytokines and inflammation  
Cytokines are small signalling molecules with a crucial role in the differentiation and 
regulation of immune cells. Cytokines have distinct properties, e.g. pro-inflammatory and 
anti-inflammatory, and are produced and secreted upon stimuli. Depending on 
stimulation, activated APC will produce different cytokines and the local cytokine profile 
will drive the polarization of T cells and hence the immune response. Moreover, the 
cytokines act in a cascade like fashion, where one cytokine stimulate the production of 
others that will reinforce the reaction. 
 
As mentioned above, a Th1 response is recognised as a pro-inflammatory response 
characterized by the classical pro-inflammatory cytokines IFN, tumour necrosis factor- 
(TNF) and IL-12. IFN is important in activating macrophages, increasing phagocytosis 
and antigen processing. TNF is a potent chemo-attractant for neutrophils and stimulates 
phagocytosis by macrophages. IFN and IL-12 are positive feedback cytokines polarizing 
naïve Th cells to Th1 cells. In addition IL-12 enhances the cytotoxicity of NK and CD8+ T 
cells (51). 
 
Th17 cells secrete the pro-inflammatory cytokine IL-17A (IL-17) and IL-17F as well as 
TNF and IL-6 and IL-21. IL-17 is a potent inflammatory cytokine, inducing the 
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expression of other inflammatory cytokines like IL-6 and IL-8 (also known as CXCL8). 
IL-17F binds to the same receptors as IL-17, indicating that they have similar functions, 
however IL-17 has a much higher affinity. Both IL-17 and IL-17F recruit and activate 
neutrophils. IL-21 stimulates Th17 differentiation, and thus serves as a positive feedback 
cytokine to maintain and amplify the Th17 subset (51,53,65). 
 
The feedback mechanism to maintain and amplify the different subsets may lead to an 
unresolved inflammatory response causing chronic inflammation which may trigger tissue 
damage and autoimmunity. Elevated levels of pro-inflammatory cytokines are linked to 
various autoimmune diseases, e.g. high levels of IL-1, IL-17 and TNF are reported in 
RA patients and IL-17 and IL-6 are highly expressed in MS patients (51,53).   
 
Autoimmunity 
The many autoimmune diseases bear evidence that the mechanisms for ensuring self-
tolerance often fail. These may be divided into single organ or systemic, the latter 
affecting multiple organs and tissues. Here I shall concentrate on human RA and an 
experimental animal model, oil induced arthritis (OIA), that we consider relevant to RA 
and which has been the main focus of the experimental work of this thesis.   
Rheumatoid Arthritis (RA) 
RA is a chronic inflammatory disease characterized by symmetric inflammation of 
peripheral joints. Infiltration of inflammatory cells in the joint synovium leads to cartilage 
destruction and bone erosion, usually causing severe pain and decreased mobility of 
affected joins. In the human RA can be divided into different clinical subtypes. The most 
prevalent of them has a late onset, usually at age 50-60 and is about three times more 
common in females than males (66,67). RA patients often develop cardiovascular diseases 
and have a 10-15 years shorter life expectancy than healthy individuals (68,69). The 
prevalence in the Caucasian population range from 0,5-1,0% and is somewhat lower in 
the Asian population (0,2-0,3%) (70).  
 
Previously the diagnosis of RA was primarily based on clinical manifestations, leading to 
diagnosis of patients with advanced arthritis only. The most widely used serologic marker 
is the serum rheumatoid factor (RF), an autoantibody against the Fc portion of the 
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immunoglobulin G molecule. However it is only present in about 70% of RA patients, 
and it is not RA specific. It is also present in other autoimmune diseases such as Sjögren’s 
syndrome as well as in up 10% of the healthy population (71). Additional molecular 
markers for RA have been identified; however, in general they are not present in all RA 
patients and may be present in other patient groups as well as in healthy individuals. They 
therefore serve more as disease indicators rather than as disease specific diagnostic 
markers. The antiperinuclear factor is highly RA specific, but has not been used as routine 
test due to laborious technique and lack of standardization (72,73). 
  
Over the last decade autoantibodies against cyclic citrullinated peptides, anti -CCP, has 
been established as a diagnostic marker of RA. Citrulline is an amino acid formed by 
post-transcriptional modification of arginine residues by the enzyme peptidyl arginine 
deiminase (PAD) and has been linked to autoimmunity (74). Anti-CCP is present in about 
80% of all RA patients, and is also present in the early stages of the disease, making it at 
better diagnostic marker than the RF factor (73,75-77).  
There is extensive variation between RA patients with regard to time of disease onset, 
disease severity, progressiveness and response to treatments. The clinical heterogeneity 
reflects the fact that multiple genes as well as environmental factors influence 
precipitation of disease. The identification of these factors will be central for diagnostic, 
prognostic, therapeutic and preventive purposes.  
 
Environmental risk factors 
Due to the higher incidence of arthritis in females, the level of sex-hormones has been 
argued to influence RA susceptibility. There are indications that pregnancy and use of 
contraceptives prevents disease or leads to disease remission. However the data are 
conflicting, and may be linked to postponing the disease rather than preventing it (78,79). 
 
Infections have been proposed as triggers of autoimmunity, however reports are 
inconclusive (70). Studies of animal models have demonstrated that bacterial and viral 
infections can trigger autoimmune responses (80,81). Several studies have reported an 
association of cigarette smoking and RA (82-89). There is an increased risk of developing 
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RA in heavy smokers (85,86,89,90). Finally, smoking is a risk factor for developing sero-
positive RA (88,90). 
 
Reports of autoimmunity and development of autoimmune symptoms following silicone 
implants, long term mineral oil administration, subcutaneous injections of adjuvants and 
accidental injections of vaccines have lead to the proposal of human adjuvant disease 
(HAD) (91-102). Recent reports have confirmed occupational exposure to hydraulic oils 
and silica as risk factors for RA (103,104). Risk factors for RA may be shared with other 
autoimmune diseases, indicating common pathogenic pathways. Smoking and exposure to 
smoking is confirmed as a risk factor for multiple sclerosis (105,106). Overt thyroid 
disease and systemic lupus erythematosus (SLE) has also been associated with smoking 
(107,108). Recently the clustering of SLE patients exposed to oil-waste reservoir was 
published, indicating an association between SLE and oil exposure (109). Exposure to 
silica is associated with an increased risk of developing SLE and anti-neutrophil 
cytoplasmic autoantibody-associated glomerulonephritis (110-112).  
 
Genetic risk factors 
In diseases where several genetic regions contribute to the development, severity and 
progression of the disease, the regions influence the phenotype of the disease in a 
quantitative manner. Such genetic regions are called quantitative trait loci (QTL). 
Identification of the QTL and the underlying genes is crucial to understand the pathogenic 
pathway. 
 
Genetic mapping of QTL 
There are two main approaches to identify QTL; linkage analysis and association studies. 
Both methods are similar in that they use genetic variation to mark genomic loci and then 
attempt to detect co-segregation of marker and disease. The most frequently used DNA 
marker is single nucleotide polymorphism, SNP i.e. a single base substitution or 
insertion/deletion.  
 
Linkage analysis is based on genetic linkage between two separate genetic loci, i.e. higher 
than random chance of joint inheritance of alleles from the two loci (113). Alleles of loci 
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on different chromosomes will not be co-inherited due to random segregation of 
chromosomes. Alleles of loci in close proximity on the same chromosome tend to be co-
inherited. They can, however, be separated due to genetic recombination, a process during 
meiosis where parts of the chromosome are exchanged between two homologous 
chromosomes. The likelihood for recombination increases with physical distance between 
the loci, but not linearly, as recombination does not happen at random, but at certain 
“hotspots” along the chromosome (114,115). Between such “hotspots” little or no 
recombination occurs, and the alleles of the loci will be inherited together in blocks. The 
combination of alleles (measured by SNPs) along such block is called a haplotype, 
consequently the blocks are referred to as haplotype blocks (116). In linkage studies it is 
tested whether a disease trait (QTL) is coinherited with a DNA marker in related subjects. 
The closer the SNP is located to the QTL, the more likely it is that the marker will co-
segregate with disease phenotype (113).  
 
Genetic association studies aim to detect association between one or more genetic 
polymorphisms and a trait in a population. It is tested if the pattern of markers for a given 
locus is at a different frequency in cases and matched controls (117). Association is based 
on linkage disequilibrium (LD) which refers to the non-random association of alleles at 
two or more loci. If the LD is high, the alleles are in disequilibrium to the assumption of 
random distribution of the alleles. Every time recombination occurs between two loci in 
the population, the linkage disequilibrium between them is weakened. Linkage spans 
generally over longer regions than LD, as there is a greater chance of random 
recombination events in unrelated individuals. Because LD spans over shorter regions 
than linkage, association analysis potentially has a higher resolution than linkage studies, 
but requires many more markers to be examined (117,118).  
 
Considerations in linkage and association studies 
Success in identification of QTL and the underlying gene by linkage studies has been 
limited to loci for monogenic diseases, like cystic fibrosis and Huntington’s disease 
(119,120). Linkage studies have limited power to detect QTL in complex diseases due to 
weak effect of individual QTL. Association studies have more theoretical power than 
linkage studies to identify QTL with modest risk (121). Aassociation studies have 
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identified several loci in complex diseases both within and outside MHC, however, many 
of them have failed to be replicated, mainly due to underpowered studies (122). 
 
A major factor of statistical power is sample size. Linkage studies are limited by the 
difficulty to get large enough sample size to generate the necessary power to detect 
linkage. There are simply not enough cases. In order to detect linkage to a marker in 
complex disease, the minimum number of affected families should be several thousands 
(121,123), an unfeasibly large family material. Association studies do not require the vast 
sample size as linkage studies; however practical concerns in collection and handling 
samples as well as cost have hampered large studies. Recent development in genotyping 
technology and the corresponding drop in cost have reduced this limitation of sample size.  
 
Sample size is not the only factor influencing statistical power. The frequency of the allele 
in the population and the magnitude of the genetic effect it gives also determine the 
power. A disease susceptibility allele with low frequency in the population, but with 
strong genetic effect requires a smaller sample size than an allele with high frequency and 
minor genetic effect in order to generate sufficient power to claim association 
(116,121,124).  
 
An important consideration of the power in a study is the correction for multiple-
hypothesis testing. Each SNP tested will represent one hypothesis, and in Genome-Wide 
association studies (GWAS) thousands to hundred thousands markers will be tested and 
some of them will associate with a QTL just by chance. Correction for multiple-
hypothesis testing will reduce the number of false positive result, but may also result in 
failure to detect a true positive result (116,125). 
  
A single QTL may harbour several independent mutations. These can be common variants 
with weak effect or rare variants with intermediate to strong effect. As examples, rare 
independent mutations in salt handling genes contribute to blood pressure variation (126), 
several alleles that independently influence development of prostate cancer have been 
identified at chromosome 8q24 and three functional variants of IFN regulatory factor 5 
are independent risk factors for SLE (127,128). Independent mutations are likely to 
distribute randomly to a reference SNP, thereby cancelling each other and obscuring 
genetic association to the reference SNP. Genetic mapping in recent founder populations 
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such as the Tristanians (Tristan de Cunha islanders), the Icelandic and the Finns have 
proven successful for identification of rare mutations. Due to isolation the population is 
made up of distantly related individuals (extended family). A mutation in the founder 
population will be amplified to a high proportion during the expansion of the population, 
giving the disease allele a high frequency (129-131). In extended families the 
recombination frequency will be lower than in a more mixed population, resulting in high 
LD over longer regions (i.e larger haplotype blocks) facilitating association studies (118).  
 
Standardization of diagnostic and phenotypic criteria is easier in isolated populations, thus 
diagnostic errors are reduced. Isolated populations often share common environment and 
culture. This reduces background noise from environmental risk factors compared with 
studies performed in non-isolated populations (131). The frequencies of alleles vary 
across human populations, which may cause difficulty in replicating association of SNPs 
to diseases among different ethnicities (132). A SNP found to associate with prostate 
cancer at chromosome 8q24 is at a higher frequency in African American, giving better 
significance of association in African Americans than in Europeans (127).  
 
Although genetic mapping has lead to the discovery of QTL for several complex diseases, 
few associated genes and causal mutations have so far been identified in the human. Re-
sequencing regions where associations are found is necessary to identify causal mutations. 
Genetic mapping of RA QTL 
Several genome scans have been performed to identify QTL involved in RA 
susceptibility. In the period 1998 - 2002, four genome scans performed in Japan, USA, 
France and UK were published (133-136). They all show significant linkage to MHC, but 
no other genetic region gave significant linkage. Lander proposed the term suggestive 
linkage for loci with p<0,05 in whole genome scans. Linkage cannot be claimed, but 
should be reported with intent to confirm the linkage in an extension study (137). By 
accepting a less strict significance, loci with suggestive linkage were reported, many of 
the suggestive loci revealed were found in more than one scan. However, extension 
studies of the scans in the US, UK and in France gave inconsistent results. The US and 
UK extension scan did not confirm the previously identified loci, but identified new loci 
with suggestive linkage (138,139). The French scan confirmed 10 out of 22 previously 
reported loci as well as identifying new suggestive loci (140). In order to increase sample 
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size and statistical power, meta-analyses have been performed for RA by compilation of 
available genome scans (141,142). These two meta-analyses are based on partly the same 
genome scans and both reveal several loci linked to RA susceptibility, seven of which are 
found in both studies. Of interest to this thesis is that both meta-analyses identify a locus 
with cytogenic location 12p12-13, a region syntenic to the region of rat chromosome 4 
containing the QTL Oia2. 
RA gene candidates in the MHC 
For a long time the only region conclusively linked to RA was the MHC or human 
leukocyte antigen (HLA) on human chromosome 6 (143,144). The most important 
candidate genes in this complex are the HLA class II genes. The association is strongest 
for HLA DRB1 alleles that encode a similar amino acid sequence, termed the shared 
epitope. The sequence is five amino acids long and resides in the hypervariable region of 
the DR1 chain. These residues form one side of the antigen presenting binding site. The 
shared epitope hypothesis postulates that the shared epitope is involved in the 
pathogenesis of RA by presentation of arthritogenic antigens. The association of HLA 
DRB1 alleles with shared epitope (alleles *0101, *0102, *0404, *0405, *0408, *1001 and 
*1402) is linked to higher risk for disease development as well as severity (145).   
RA gene candidates outside the MHC 
In the past few years, a few gene candidates for RA have been reported. In 2004 Begovich 
et al. published the association of PTPN22 to RA (146). The gene was found through 
candidate gene study after a locus was identified in a US genome-wide association study. 
Association was replicated in affected families study, and has further been replicated in 
caucausian populations by other groups (147-154) but not in Japanese and Korean 
populations (155,156). PTPN22 is however associated with RA in South Asians in the UK 
and in a Colombian population (157,158). PTPN22 encodes a cytoplasmic protein tyrosin 
phosphatase involved in negative regulation of T cell activation. Begovich et al. reported 
a missense single nucleotide polymorphism (C1858T) that altered the proteins function, 
leading to T cells with a lower threshold for activation (146). 
 
A Japanese genome scan reported a locus spanning over a region containing all known 
genes encoding peptidylarginine deiminase, PAD. In a Japanese case control study using 
SNP markers in the PAD genes 1-4, association was found to variants of four SNPs in 
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PADI4 (159). Given the fact that auto-antibodies against citrullinated proteins are present 
in most RA patients, an association to a citrullinating enzyme is interesting. Association 
to PADI4 was replicated in a Japanese study (160) and association has also been found in 
Chinese and Korean populations (161,162). However, association to PADI4 in Caucasians 
has been conflicting; no association were found in a French, UK or Hungarian studies 
(163-165) and Plenge et al. reported association in a north American cohort, but not in a 
Swedish (166). In another UK study a two-marker haplotype for PADI4 was weakly 
associated with RA, and PADI4 were over-expressed in cases compared to controls (167). 
 
Another candidate gene originally found in Japanese studies is the Fc receptor-like 3 
gene. A SNP in the promoter region is associated with RA, SLE and autoimmune thyroid 
disease (168). This SNP has also been associated with RA in Caucasians (169-171). Other 
candidate genes reported are the T cell immunoglobulin and mucin-domain-containg  
receptor -1(TIM1), cytotoxic T lymphocyte antigen-4 (CTLA4), solute carrier 22A4 
(SLC22A4), tumor necrocis factor receptor associated factor 1 (TRAF1), Interleukin 1 
(IL1b) and the programmed death-1 gene (PD1) (172-178).  
Experimental animal models for autoimmunity 
Another approach to obtain gene candidates is to develop experimental autoimmune 
animal models and perform genome scanning to detect QTLs, and see whether the 
syntenic regions in the human is associated with the disease in question. Animal models 
provide a tool to control both environmental factors as well as the genetics. One of the 
great advantages is the possibility to manipulate the animal genome either through 
breeding (congenic strains and advanced intercrossed lines) or advanced genome 
technology (transgenic or knock-out strains) (179,180). 
 
A number of different animal models exist for many different autoimmune diseases and 
other diseases like cancer and hypertension as well as infection models. Some inbred 
strains develop a disease spontaneously, other diseases can be induced. The basis for all 
experimentally induced models is to find two strains with different phenotype to the same 
stimulation. In the rat, the Dark Agouti (DA) strain is susceptible to a number of 
autoimmune diseases; experimental autoimmune encephalomyelitis (EAE), experimental 
allergic neuritis, experimental allergic uveitis, experimental autoimmune thyroiditis as 
well as all experimental arthritis models (181-189). Of all strains tested so far, DA is the 
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only strain that is susceptible to oil induced arthritis (OIA), and in other arthritis models 
the DA rat consistently display a more severe arthritis than other susceptible strains. 
Similarly, the inbred rat strain PVG is resistant to the experimental models mentioned 
above (185,186,188,189). Comparing the genome of the DA and PVG rat strains have 
contributed in isolating QTLs for several different diseases. For a complex heterogeneous 
disease like RA, no experimental model will display all the features of RA, but all the 
different models may contribute in the understanding of the pathogenesis of RA. Central 
in this thesis is oil induced arthritis in the susceptible DA rat and resistant congenic 
strains. 
 
Oil induced arthritis (OIA) 
OIA is induced by a single intradermal injection of Incomplete Freund’s adjuvant (IFA) at 
the base of the tail. IFA is an adjuvant used in many different immunization protocols to 
induce experimental inflammatory diseases. It has also been used as an adjuvant in 
vaccination protocols for humans and livestock. Its purpose as an adjuvant (from Latin: 
adjuvare; to help) is to stimulate the immune system to raise a strong response against the 
compound in the vaccine (190). IFA is composed of 85 % mineral oils (Bayol F) and 15% 
of the emulsifying agent Arlacel A (Mannide monooleat). 
 
OIA is characterized by a mild inflammation in the small joints of the hind paws and 
ankles 12-15 days post injection in susceptible rats. Sometimes inflammation also 
progresses to the front paws. The inflammation is monophasic, it spontaneously subsides 
by day 45, with little or no erosion of joints as reported by Cannon et al and Lorentzen et 
al (188,191). However, the course and severity of disease can be altered in a different 
environment. Compared to the mild disease development reported by Cannon et al and 
Lorentzen et al, DA rats housed in the animal facility in Domus Medica, Oslo, Norway 
almost always develop relatively severe arthritis in all four paws upon arthritis induction, 
and inflammation does not subside without treatment with anti-inflammatory drugs.   
 
Adoptive transfer of T cells can transfer disease (192,193). OIA is influenced by genes 
both within and outside of the MHC, as shown by testing different MHC congenic strains. 
Compared with the DA strain, the PVG.1AV1 strain develops mild disease with 
incomplete penetrance. The difference in susceptibility between DA and the MHC 
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identical PVG.1AV1 can only be explained by influence from genes that do not reside in 
MHC (194).   
 
Identifying QTLs in animal models 
The strategy to identify QTLs in animal models is very much the same as identifying 
QTLs for disease in humans, but with one important difference: the control over genetics. 
A genetic linkage map is created by genome scanning of a population of rats produced by 
crossing different stains with a different phenotype to a challenge, in our lab we used DA 
(susceptible to OIA) and PVG (resistant to OIA). After a DAxPVG cross, the 
heterozygous F1 generation is intercrossed to produce an F2 generation. Due to 
Mendelian law of random segregation of chromosomes, any individual in the F2 
generation will be a mix of homozygous DA (DD), heterozygous DA/PVG (D/P) or 
homozygous PVG (PP). Adding to this, there will be recombination events. A QTL can be 
mapped by testing the F2 population for the phenotype; susceptibility, and compare with 
the genotypes. If a genotype for any of the markers is co-inherited with susceptibility, the 
marker is linked to disease. In OIA, three QTLs were found by genome scanning of an F2 
population: Oia1 within the MHC on chromosome 20, Oia2 on chromosome 4 and Oia3 
on chromosome 10 (195).  
 
Congenic strains for fine mapping  
The identification of a QTL from a F2 linkage map is crude. One strategy to fine map the 
QTL interval is to generate congenic strains, here illustrated with the identification of loci 
for OIA using DA (susceptible) and PVG (resistant) as examples. (Fig.3). To generate an 
Oia2 congenic strain, F1 offspring from a cross between DA and PVG are backcrossed 
with the DA strain. The F2 generation is genotyped and individuals heterozygous for 
markers in the Oia2 QTL are selected for further breeding and backcrossed with DA. This 
selective breeding and backcrossing is continued for at least 10 generations to get rid of 
undesired PVG genomic background. After the N generation, crossing of two 
heterozygous congenic animals will give rise to homozygous offspring which have the 
PVG alleles in the Oia2, but the rest of the genome is DA. The Oia2 congenic rats are 
resistant to oil induced arthritis, whereas DA rats are not. Continued breeding of the 
congenic strain in heterozygous form has an advantage due to the potential recombination 
event in the congenic interval. Further backcrossing into the parental DA strain may 
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produce intra-congenic recombinants with a contracted congenic region compared to the 
original congenic strain, thus providing a more precise mapping of the QTL.  
 
 
 
 
Figure 3. Generation of a congenic strain through marker selected breeding. 
Two inbred rat strains are crossed to produce a F1 heterozygous population. The F1 are then backcrossed 
with one of the parental strains, in this case DA. Due to recombination events, PVG chromosomal regions 
are introduced on the DA background. Offspring heterozygous in the region of interest, Oia2, marked with 
an arrow, are further backcrossed with DA for n generations. In the end crossing offspring heterozygous for 
the Oia2 locus will yield a strain with PVG genotype in the Oia2 locus on DA background. 
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A narrower congenic interval will ease the search for gene candidates, as there will be 
fewer genes to test. Breeding of congenic strains has proven successful in narrowing 
down the gene candidates behind QTL in various experimental models. Previously Ncf1 
has been identified as an arthritis severity regulating gene in the rat model pristane 
induced arthritis (PIA) by breeding of congenic and intra-congenic recombinant strains 
(196). The congenic interval was narrowed to a segment of approximately 300 kb, 
harbouring only two genes. Sequence analysis revealed polymorphisms in the Ncf1 gene. 
The polymorphism in the Ncf1 gene has a functional outcome. The variant in the arthritis 
prone DA rat leads to reduced oxidative burst compared to the variant in the resistant 
congenic rat (196). Furthermore, in the mouse a mutation in Ncf1 leads to an alternatively 
spliced mRNA and a truncated protein with loss of function. This mutation was 
backcrossed into another strain, allowing testing for experimental autoimmune models. 
Congenic mice with the mutated Ncf1 show increased severity of collagen induced 
arthritis as compared with mice with normal Ncf1 (197). In addition to high resolution 
mapping, the generation of congenic strains is useful as it makes a polygenic disease 
monogenic, which will help unraveling the pathogenic pathway of a disease contributing 
gene, without the contaminating effect from other QTLs (180,198).  
 
An alternative way to fine-map QTL is to generate advanced intercross lines, AIL. 
Generation of AIL is not based on marker selected breeding couples, but controlled 
random intercross for every generation. The genetic recombination events in every 
intercross will accumulate for every generation. It is important to keep a large number of 
breeding pair to avoid brother sister mating to prevent homozygous chromosomes (hence 
the term controlled random intercross). After n generations the accumulated 
recombinations will result in a mosaic genome between the two parental strains. A large 
number of generations will provide a high resolution linkage map (179). In addition to the 
possibility to fine-map QTLs, AIL is well suited to study gene-gene interactions, such as 
epistasis, a phenomenon where one gene may influence the phenotypic expression of 
another. A partial AIL revealed epistatic interactions and sub-division of one locus into 
three loci in a mouse EAE model (199).  
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From isolated QTL to structural gene 
Theoretically the structural gene behind a QTL can be identified by the continued 
production of intra-congenic strains with progressively narrower congenic region until the 
congenic region spans only over a single gene. There are practical limitations to this 
approach. The generation of intracongenic strains is dependent on recombination event 
within the congenic region. If the congenic region is narrow, there will be less chance for 
a recombination in the desired region. This necessitates a vast number of breeding pairs 
and increased housing expenses. The detection of a recombinant may also be hampered 
by lack of a genetic marker that is polymorphic between the parental strains. 
 
Previously, genes in the congenic region had to be identified by cumbersome methods 
like chromosome walking or exon trapping. The release of the mouse and rat genome 
sequence has greatly eased the search for candidate genes. With the sequences of most or 
all genes in the congenic region available, together with improved software to predict 
protein function, researchers could make a qualified guess about gene candidates. For 
identification, the candidate genes have to be tested for features that can explain the 
difference in phenotype. This includes identification of possible differences in sequences, 
splice patterns, expression levels and functional properties of the encoded proteins.  
 
From animal model to human 
Through precise mapping of a QTL, the syntenic region in the human can be tested for 
association to the disease. Alternatively, if the QTL mapping in an animal model resulted 
in a concrete gene candidate, the orthologoue gene and closely related genes in the 
syntenic region can be tested for association. The animal model serves as a search light, 
identifying interesting regions/genes relevant for human disease. In 2001 Barton et al 
reported a linkage study on human chromosomal regions syntenic to five QTL in the rat 
that regulate experimental arthritis (200). Linkage was reported to human 17q21-25, 
syntenic to Oia3. The other QTLs; Oia2, Pia4 (pristane induced arthritis locus 4), Cia4 
(collagen induced arthritis locus 4) and Aia2 (adjuvant induced arthritis locus 2) did not 
show any linkage in this study, however the region 12p12-11 syntenic to Oia2 locus show 
linkage in two meta analyses reported by Fisher et al  and Choi et al (141,142).  
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Aims of the study 
At the start of my study, Lorentzen at Karolinska Institutet, Stockholm, had just localized 
Oia2 to the distal part of chromosome 4. In Oslo we had mapped the NK cell gene 
complex (NKC) to this genetic region. The work was based on genetic analyses of back-
crossed progeny, where we found a crossing-over frequency of 0.4 %, i.e. < 0.5 cM, 
between the genes flanking the complex. This was identical to the crossing-over 
frequency described for the mouse NKC by Wayne Yokoyama, suggesting that the size of 
the complex and number of genes within would be relatively modest (201). We therefore 
embarked on making a total inventory of the rat NKC, based on a PAC library from the 
Wellcome Trust Centre for Human Genetics, Oxford. The work turned out to be more 
difficult than anticipated, as the gene complex proved to be much larger than predicted 
from the genetic map. We were subsequently steamrolled by the rat genome initiative, 
whereby the complete genome was sequenced with, for a mammalian genome, 
unprecedented rapidity.  
 
The NK cells are potent immunoregulatory cells through their production of cytokines, 
thus the NKC was a likely candidate region for harbouring the Oia2 locus, which revived 
our interest in complete characterization of the complex. The interest subsequently faded 
with the discovery that Oia2 mapped outside the NKC (paper II). However, as incomplete 
and partly erroneous reports of the gene content of the rat NKC later were published by 
others, based on in silico gene predictions from the released genomic sequence, we 
considered it worthwhile to sum up our work on the characterization of the rat NKC, 
which includes the cDNA cloning of the majority of the predicted CTLR genes and 
analyses of their expression patterns (paper I). The work also clarifies why we consider it 
useful to categorize the genetic region containing newly detected related genes just 
upstream of the NKC (the APLEC) as a separate gene complex (paper III). 
 
As a preparation for identifying functional loci linked to the NKC, we had made congenic 
strains for this region, based on the two parental strains, PVG and DA.  Coincidentally, 
the two strains were the same that Lorentzen had used in his studies of oil induced 
arthritis. The idea that the Oia2 locus was linked to the NKC was therefore easy to test. 
The first congenic strains produced in Oslo did indeed confirm linkage between Oia2 and 
the NKC. However, by narrowing the transferred region through continued back-crossing 
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the genes in the NKC had to be excluded. A novel recombinant strain, R2, back-crossed 
from the OIA resistant strain R1, turned out to be OIA susceptible, although the whole 
NKC of R2, like R1, exhibited the PVG haplotype. Genotyping showed that the haplotype 
block transferred from the PVG strain had been shortened on the centromeric side of the 
NKC, thus positioning the QTL to this region. Incidentally, at the same time genes 
encoding novel CTLR receptors were reported to map within or close to the NKC in the 
mouse and the human. However, they exhibited different cellular expression patterns from 
most NKC encoded receptors. Supported by our crude rat maps, it was clear that if the 
novel identified genes had rat orthologues, they would be positioned proximal to the rat 
NKC, in the middle of the chromosome region where we had mapped Oia2. Based on 
deduced cellular expression patterns and sequence features, the novel receptors seemed to 
be involved in the regulation of activation of professional antigen presenting cells, 
including DC. They therefore seemed to be ideal candidate genes for Oia2. Due to 
limitation of resources we divided the working tasks between Stockholm and Oslo, so that 
they in Stockholm continued back-crossing of the DA.C4PVG congenic strains to further 
narrow the region containing the Oia2 gene, whereas we in Oslo should characterize the 
genetic region containing the novel genes, which we called APLEC.  
 
Both working tasks were successful. By the generation of a series of recombinant strains 
in Stockholm (paper II and paper IV), the Oia2 was conclusively mapped to the novel 
gene complex. By then we had characterized the APLEC both in the rat, mouse and 
human. In addition to cDNA cloning of novel genes in all three species, we had 
sequenced and compared gene expression patterns of the genes in the OIA susceptible DA 
strain and the two resistant strains PVG and LEW. Interestingly, the DA strain turned out 
to be a natural knock-out strain for one of the genes, Dcar1 (dendritic cell activating 
receptor gene 1). 
 
The conclusive mapping of the Oia2 to the APLEC represented an important milestone, 
the end of a long search and the starting point of novel studies, fanning out in different 
directions. One of these is to see whether the homologous gene complex is associated 
with autoimmune diseases in the human (paper IV), the other to try to pinpoint the roles 
of the APLEC receptors in the pathogenic mechanisms leading from application of oil to 
the skin to development of inflammation in distant joints. 
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Summary of specific aims 
 
1) Characterize the Natural Killer gene complex, NKC, in terms of gene content and 
gene expression programs. 
 
2) Fine-map the chromosomal position of Oia2.  
 
3) Characterize the antigen presenting cell lectin-like receptor gene complex, APLEC, in 
terms of gene content and gene expression programs. 
 
4) Identify the structural gene within APLEC associated with OIA.  
 
5) Identify pathogenic mechanisms leading from application of oil to the skin to 
development of inflammation in distant joints.  
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Summary of results 
Paper I 
The complete inventory of genes in the rat natural killer cell gene complex. 
The rat NKC, which spans ~ 3.3 million base pairs (Mb), can be divided into four regions. 
Flanking the complex on the centromeric side is the ~ 0.8 Mb region I containing four 
genes encoding NKR-P1 receptors and 10 genes (plus a gene fragment) encoding their 
CLR counter-receptors. On the telomeric side is the large (~1.8 Mb) region IV containing 
altogether 34 Ly49 genes (including several pseudogenes) and the Klrh1 gene. Just 
centromeric to the Ly49 region is the much smaller (~ 0.3 Mb) region III containing eight 
genes encoding the CD94/NKG2, KLRE/KLRI and KLRK1 (NKG2D) receptors. The 
cDNA cloning and expression analyses of the genes from these three regions of the rat 
NKC have previously been reported elsewhere. Intercalated between the NKRP1/CLR 
and CD94/NKG2 clusters is a 0.3 Mb region which contains the Lox1 gene encoding the 
oxidized LDL receptor, previously described by others. In silico homology screening 
against BAC clones and the whole genome sequence (www.ensembl.org/ 
Rattus_norvegicus) with mouse and rat sequences as probes revealed eight other genes in 
region II:  Cd69, Clec2m, Clec12a, Clec12b, Clec1b, Clec9a, Clec1a and 
Dectin1(Clec7a), which were all cDNA cloned. Apart from the CLR genes, the genes 
encoded by regions I, III and IV are expressed predominantly by NK cells. In contrast, the 
genes within region II are expressed by other cell types, in particular myeloid, but also 
endothelial and testicular cells. With a total gene content of 67 genes predicted to encode 
group V CTL receptors, the rat NKC represents one of the largest known mammalian 
gene complexes consisting exclusively of paralogous genes.  
 
 
Paper II 
High resolution mapping of an arthritis susceptibility locus on rat chromosome 4, and 
characterization of regulated phenotypes. 
A genome scan had previously mapped the QTL Oia2 to the distal part of rat chromosome 
4, including the natural killer cell gene complex (NKC). In this paper we fine map Oia2 
by testing a series of DA.C4PVG congenic strains generated through marker assisted 
transfer of parts of the distal chromosome 4 from the OIA resistant PVG strain to the 
genetic background of the susceptible DA strain. The first results from Oslo showed that 
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Oia2 must reside just proximal to the NKC, but outside this gene complex. Subsequent 
analyses of novel recombinant strains in Stockholm reduced the genomic region 
containing the QTL to approximately 1.2 Mb, containing a limited number of genes. The 
region included the CTLR genes in the newly discovered APLEC gene complex. 
 
 
Paper III 
Identification of lectin-like receptors expressed by antigen-presenting cells and 
neutrophils and their mapping to a novel gene complex. 
Independent recent reports from the mouse and the human had revealed genes encoding 
novel CTLR preferentially expressed by professional APC and were variably suggested to 
lie close to or within the NKC. From our work on the rat NKC we considered it more 
likely that putative rat orthologues were localized together and outside the NKC, within 
the region where we had mapped Oia2. We therefore considered these genes strong Oia2 
candidates and decided to identify the related genes in the rat. Although the work started 
before the genomic sequences of the mouse and the rat were released, we succeeded in 
cDNA cloning all the rat orthologues plus novel related genes, altogether eight genes 
predicted to encode type II CTL receptors, named macrophage inducible C-type lectin 
(Mincle), macrophage C-type lectin (Mcl), dendritic cell activating receptor (Dcar1) and 
dendritic cell inhibitory receptors 1 to 4 (Dcir1-4). The rat orthologue of dendritic cell 
associated lectin-2 (Dectin2), turned out to be a pseudogene (rat Dectin2p). We also 
reported the cDNA cloning of two related novel human genes, DECTIN2 and MCL, and 
five novel mouse genes: Dcir2-4, Dcar1 and Dcar21. We showed that the genes mapped 
together ~ 6 Mb proximal to the NKC, differed from the KLR encoded by the NKC by the 
preservation of amino acids involved in saccharide binding, hence their classification as 
group II in the C-type lectin super family, and that they were preferentially expressed by 
professional APC (dendritic cells, macrophages and B cells) plus neutrophils.  Based on 
sequence, expression and chromosomal mapping analyses we proposed that the genes 
defined a novel, evolutionary conserved gene complex, which we named the antigen 
presenting cell lectin-like receptor gene complex, APLEC.  
 
                                                 
1 We originally submitted the mouse and rat Dcar genes as Aplra1 and -2, but changed nomenclature when 
mouse Dcar2 was reported by others just before our paper was published. 
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Paper IV 
Association of arthritis with a gene complex encoding C-type lectin-like receptors 
The aim with this work was to pinpoint the structural gene associated with Oia2 and to 
see whether the syntenic chromosomal region is associated to RA in the human. 
Continued back-crossing of DA.C4PVG congenics with DA eventually produced the OIA 
resistant recombinant strain, R17 (17th generation of back-crossing). Here, the 
chromosomal interval containing the protective PVG haplotype block was fully contained 
in the region flanked on the outside by the genetic markers D4Kir12 and D4Kir55. The 
distance between these two markers is only 0,8Mb. The only detectable genes in this 
region were the APLEC genes Mincle, Mcl, Dcar1 and Dcir1-3. Quantitative PCR 
analyses showed significant expression differences between DA and R17 for Mincle, Mcl, 
Dcar1 and Dcir3. cDNA sequencing of the strains, revealed a few largely conservative 
missense mutations in DA versus the OIA resistant PVG and LEW alleles for Mincle, 
Dcir1 and Dcir2. The most striking finding was an early nonsense mutation in Dcar1 in 
DA, but not in PVG or LEW. DA thus represents a natural knock-out strain for this gene. 
The genes in the syntenic human gene complex were tested for association to arthritis by 
SNP typing of ~ 2 000 RA patients and matched controls. Of 35 SNPs tested, the SNP 
rs1133104, lying within the human DCIR gene, showed statistically significant 
association with odds ratio of 1.27 (95% confidence interval 1.06-1.52; p= 0.0073) in 
patients negative for antibodies to cyclic citrullinated peptide (anti-CCP). We thus 
conclude that the gene complex APLEC is associated with arthritis both in the rat and in 
the human. In the rat, the most likely Oia2 candidate is Dcar1, whereas in the human 
association to RA was to DCIR. 
 
Paper V 
Effect of APLEC receptors on cytokine expression in oil induced arthritis (OIA) in rats. 
In this work we aimed to identify the role of the candidate genes in the mechanisms 
leading to inflammation in the joints following application of oil to the skin. Previous 
adoptive transfer experiments had indicated that the arthritogenic response is initiated in 
the lymph nodes draining the site of oil injection. Here we measured the expression levels 
of APLEC genes and selected cytokines by quantitative PCR in draining and non-draining 
lymph nodes of OIA susceptible DA rats and resistant congenic R17 rats at different time 
points following skin application of adjuvant oil. The most conspicuous finding was early 
strong up-regulation of Dcar1 mRNA in both strains, followed by strong up-regulation of 
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Il17 in DA, but not in R17 rats. In R17 rats the early surge of Dcar1 mRNA is likely to 
result in rapid upregulation of this receptor in the lymph node, whereas in DA the non-
sense mutation precludes synthesis of the Dcar1 protein. The temporal link between 
Dcar1 and IL-17 synthesis suggests causal relationship between the two events. IL-17 is a 
pro-inflammatory cytokine, produced by the T helper subset referred to as Th17 cells, 
which has been linked to arthritis and other autoimmune and inflammatory diseases. We 
therefore propose that the Dcar1 protein is involved in helper T cell polarization, where 
oil stimulation in the absence of Dcar1 protein skews the response towards Th17 
differentiation and IL-17 production, which in turn leads to the subsequent inflammatory 
response in the joints.  
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General Discussion 
The most important discovery in this work is the identification of the gene complex 
APLEC and the linkage of this complex to arthritis in both rat and human. I here aim to 
discuss my results in the context of novel findings. 
 
NKC vs APLEC 
In papers I and III we characterize two gene complexes, the NKC and the APLEC, lying 
fairly close together and consisting of related receptors. In the mouse and rat NKC, the 
large collection of KLR genes is uninterrupted by other genes, except for single intruding 
non-CTLR gene, encoding GABA(A) receptor-associated protein like 1, splitting blocks 
II and III of the NKC. This is also observed in the human NKC. The much smaller 
APLEC contains nothing but CTLR genes. In both mouse and rat the two complexes are 
separated by a chromosomal region of 5 - 6 Mb containing a variety of non- C-type lectin 
superfamily genes. In the human the distance between the complexes is less; 
approximately ~ 1.2 Mb, also separated by non- C-type lectin superfamily genes. The 
group II genes cluster together at a distance from the group V genes in all four orders of 
mammals investigated: dog, cattle, human and rodents (202). 
 
Within the large C-type lectin superfamily, the receptors encoded in the NKC and APLEC 
are classified as belonging to different subgroups, groups V and II, respectively. 
Evolutionary the group II C-type lectins seem older as they have retained the Ca++- 
dependent carbohydrate binding domain, whereas group V do not have a functional form 
of this domain (8). Group II, but not group V lectins have been described in the teleost 
fish, Fugu rubipes (203). Clusters of group V genes were reported in the teleost 
Oreochromis niloticus (204). However, according to the authors, the Oreochromis KLR 
loci are not true orthologues to the mammalian KLR, but paralogues, signifying that the 
clusters have developed after the divergence of teleostean and mammalian lineages. 
Interestingly, a multigene family of immune related lectin-like receptors cloned from 
Fugu rubipes were reported (205). The receptors belong to the group II lectins and Mincle 
is among the mammalian proteins with greatest homology to these genes, suggesting 
common ancestry.  
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APLR function 
So far knowledge about the functional roles of the APLR is limited and their ligands are 
largely unknown. In contrast, the functional properties of several KLR have been 
extensively studied. As detailed in the introduction, many of the KLR regulate NK cell 
activation by transducing inhibitory or activating signals upon ligand binding. The 
signalling properties are linked to characteristic sequence features of the receptors, 
notably ITIMs in the cytoplasmic tails of the inhibitory receptors, and positively charged 
amino acids (arginine or lysine) in the TM region of the activating receptors, mediating 
association with ITAM containing adapter proteins. ITIMs or the presence of arginine in 
the TM region are seen in some of the APLR, suggesting that they similarly take part in 
regulation of cell activation. In the case of KLR the lysis of target cells by NK cells 
permits unequivocal definitions of the terms “activating” and “inhibitory”. For APCs the 
consequences of activation is less clear-cut and activation can lead to the generation of 
inhibitory (tolerogenic) DC or regulatory DC that modulate activity. Thus in the 
following, the terms “activating” and “inhibitory” simply refers to whether the receptors 
mediate signals through ITAMs (contained in associated adapter proteins) or ITIMs, 
independent of the final cellular output.   
 
Inhibitory receptors 
Human DCIR, as well as mouse and rat Dcir1 and - 2 contain an ITIM in their 
cytoplasmic tail, pointing to inhibitory roles. Human DCIR has been shown to associate 
with SHP1 and SHP2, two tyrosine phosphatases that associate with inhibitory receptors 
in the Ly49 family of KLRs, corroborating that DCIR is an inhibitory receptor (206,207). 
The observation that human DCIR is down-modulated in activated neutrophils, has led to 
the proposal that DCIR represses the activation of neutrophils (208). Kanazawa et al. has 
shown that the ITIM of mouse Dcir1 can inhibit the Ca++ mobilization and tyrosin 
phosphorylation. Following mutation of the tyrosine in the ITIM to phenylalanine, Dcir 
failed to block Ca++ mobilisation and tyrosine phosphorylation (17). Thus human and 
mouse DCIR act as inhibitory receptors, dependent upon their ITIM. Mouse Dcir2 also 
contains an ITIM, but apart from demonstration of internalisation of the receptor no 
functional studies of Dcir2 regarding its signalling properties have been published (209). 
The ITIM is conserved in both mouse and rat and it is highly likely that Dcir2 is a 
functional inhibitory receptor in the two species.  
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Activating receptors 
MINCLE, DECTIN2, BDCA-2 and Dcar2 have all been reported to associate with the 
ITAM-containing adapter protein FcR (18,210-212). In KLR, the rule is that the 
association to FcR requires a positively charged amino acid (arginine, R or lysine, K) in 
the TM region of the receptor close to the extracellular side to match the position of the 
negatively charged amino acid (aspartic acid, D) in the TM of FcR (see Fig.4) (23,213). 
The TM regions of APLRs were predicted using Smart and InterProScan and are 
indicated in fig.4. MINCLE has a positively charged amino acid (R) in the TM region, 
corresponding with the position of the negative charge in the FcR. Yamasaki et al 
demonstrated association of MINCLE and FcR after co-transfection and 
immunoprecipitation. Mutating the arginine to the neutral isoleucine abolished the 
association. Furthermore, endogenous MINCLE and FcR were co-immunoprecipitated in 
lysates from mouse peritoneal macrophages, confirming the association. Thus, Mincle 
seems to associate with FcR in a conventional manner (210). 
 
In contrast, Dectin-2, BDCA-2 and Dcar1 and Dcar2 do not have a positively charged 
amino acid in the TM region. Kanazawa et al. reported that mouse Dcar2 associate with 
FcR. The authors suggested that an arginine located on the border of the predicted TM 
and cytoplasmic tail of the receptor was in part responsible for the association (18). 
Dectin-2 also contains an arginine and human BDCA-2 a lysine (K) in the same position 
(see fig.4). It should be noted, however, that single-pass transmembrane proteins often 
have positively charged amino acids in this position, of importance for the correct 
orientation of the TM in the membrane during protein synthesis (214). 
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Figure 4. Relative positions of the charged amino acids of FcR and associating receptors. 
A) The position of the positively charged amino acid in Mincle, Dcar1, Dectin-2 and DLEC/BDCA2 is 
indicated with a red circle. Mincle has an arginine in the position corresponding to the position of aspartic 
acid (D) in FcR. Dcar1 and Dectin-2 contains an arginine whereas BDCA-2 contains a lysine in the TM 
border. (Adapted from (23)).  B) The predicted TM of Mincle, Dcar1, BDCA-2 and Dectin-2 are indicated 
in bold. In Mincle the arginine responsible for association with FcR is marked with blue. The positive 
charged amino acid suggested to facilitate adapter association in Dcar1, BDCA-2 and Dectin-2 is marked 
with red. 
 
   
In the case of mDcar2, the data supporting the association with FcR are weak. Co-
transfection of Dcar2-Flag and FcR gave only modest surface expression as detected 
with anti-Flag, and mutating the arginine to neutral or negatively charged residues (R/I, 
R/D) did not alter Dcar2-Flag surface expression in co-transfection studies with FcR 
(18). This indicates that the possible association between Dcar2 and FcR is not mediated 
by the arginine on the TM/cytoplasmic border in Dcar2. Despite several attempts to 
reproduce the results by co-transfection of rat Dcar1-Flag and FcR in our laboratory, we 
obtained only very weak to no surface expression of the receptor. A possible explanation 
is that Dcar1 needs another receptor chain to form a stable complex for expression, as is 
the case with the CD94/NKG2 and the KLRE/I heterodimers (10,22). It may also be that 
FcR is not the natural adapter, and that surface expression of Dcar1 requires association 
with a yet unidentified adapter protein. 
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In the human, association of BDCA-2 with FcR was shown in a transfectant cell system 
(212). Here chimeras of BDCA-2 with the TM domain from DCIR or MCL were co-
transfected with FcR. Precipitation of FcR was not possible after co-transfections with 
the chimeras, only after co-transfection with wild type BDCA-2 (212). The TM of 
wildtype BDCA-2 and MCL differ only in 6 residues, and out of these three are polar in 
BDCA-2 and neutral in MCL. This difference in polarity may be involved in the 
association with the adapter protein, either directly or indirect through another 
unidentified protein. 
 
In the mouse, Dectin-2 was reported to associate with FcR, as demonstrated by co-
precipitation after co-transfection (211). Mutating the arginine on the TM/cytoplasmic 
border to valine (neutral) did not affect the association of FcR after co-transfection, 
indicating that the arginine residue is not responsible for association between receptor and 
adapter protein (211). A motif in the intracellular domain of mouse Dectin-2 appears to be 
important for association with FcR. In co-transfection studies with Dectin-2 mutants, a 
mutant lacking the intracellular domain (aa1-14) resulted in a poor precipitation of FcR, 
whereas transfection of Dectin-2 lacking aa1-7 did not alter the precipitation of FcR 
compared with wildtype Dectin-2. Thus amino acids 8-14 seem to be important for 
association to FcR (211). The protein sequence in the intracellular domain close to the TM 
domain is conserved in rodent Dectin-2 and Dcar1 and to a certain degree in human Dectin-
2 and BDCA-2, but not in Mincle (figure 5).  
 
 
 
 
Figure 5. Amino acids 1-14 of intracellular domain of selected APLRs.  
The aminoacid sequence 8-14 (shown in bold) is conserved between rat and mouse Dectin-2 and Dcar1 and 
to some degree in human BDCA-2 and Dectin-2, but not in Mincle or any other of the APLRs. 
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This indicates that a motif in the intracellular domain may be involved in the association of 
receptors and FcR. It should be noted, however, that except for Mincle, the association to 
FcR has been demonstrated only through co-transfection of APLR and FcR in cells with 
no endogenous APLRs or FcR. The artificial (over)expression of receptor and adapter 
protein may cause low-affinity, non-functional interactions. Association therefore needs to 
be verified in cells with endogenous receptor and adapter protein. 
 
APLR ligands 
Few functional studies of the receptors have been reported, however the identification of 
ligand may give cues about the receptors function. As detailed previously, the receptors 
have the conserved domains for Ca++ binding, they are “true” lectins and this indicates 
that the APLR are involved in carbohydrate binding and possibly have a role in pathogen 
recognition. 
 
Mouse Dectin-2 has been shown to bind hyphae of the fungi Candida albicans, 
Microsporum audouinii and Tricohophyton rubrum and is highly specific for mannose. 
Furthermore, mouse Dectin-2 has been shown to recognise extracts from house dust mites 
and the mold Aspergillus fumigatus, inducing production of proinflammatory lipid 
mediators. The recognition of these pathogens indicates a role for Dectin-2 as a pattern 
recognition receptor (211,215,216).  
 
Human and mouse MINCLE were reported to bind C. albicans inducing production of 
TNF (217,218). Another ligand for Mincle has been identified. Yamasaki et al 
demonstrated that mouse Mincle bind SAP130, a subunit of nuclear ribonucleoprotein 
released from dead cells, indicating that Mincle can sense damaged cells and function as a 
“danger receptor” (210). However, the same group reported recently that mouse Mincle 
recognises Malassezia sp and that recognition were abolished when the putative mannose 
binding domain was mutated (219). Furthermore Mincle was recently shown to recognise 
the glycolipid Trehalose-dimycolate (TDM) from the cell wall of Mycobacterium 
tuberculosis. TDM stimulated macrophages produce inflammatory cytokines and nitric 
oxide. This production was abolished macrophages derived from Mincle deficient mice 
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(220). This is corroborated by another group (221). Together the data suggest that Mincle 
has a role as a pattern recognition receptor. 
 
No ligands have been identified for the other APLEC receptors. Still, the main hypothesis 
is that these receptors are pattern recognition receptors. Human DCIR, MCL and DLEC/ 
BDCA-2 as well as mouse Dcir-2 and Dcar-1 have been reported to be internalized upon 
crosslinking or binding of antibody (209,222-225). Internalization is no evidence of 
pattern recognition as most receptors will become internalized upon crosslinking or 
binding of ligand, however in the case of hDCIR, mDcir-2 and mDcar-1 it has been 
demonstrated that internalisation leads to delivery of antigens to the antigen processing 
pathway (209,224,225). Furthermore, binding of antibody to human DCIR and BDCA-2 
resulted in decreased production of the major antiviral cytokine IFN- from plasmacytoid 
dendritic cells (212,223,224). 
 
The recognition of microbes and internalization of receptors upon binding with 
ligand/antibody, points towards a role for the APLR as pattern recognition receptors. The 
functional data also confirm that the receptors are involved in the regulation of the 
activation status of dendritic cells and mediate immune response by shaping the cytokine 
profile.  
 
APLR in autoimmune diseases 
In paper IV we identify Dcar1 as a possible causative genetic factor for OIA and report 
the association of a SNP in APLEC close to DCIR with human RA. Sequence analysis of 
the rat genes revealed differences in Mincle, Dcar, Dcir1 and Dcir3 between the two 
strains, and expression analysis revealed differences in mRNA for Mincle, MCL, Dcar1 
and Dcir3. The missense mutations found in Mincle, Dcir1 and Dcir2 are not likely to 
have a serious influence on protein function, and the effect of the expression differences 
are unclear, nevertheless the genes cannot be excluded to not have any impact on arthritis 
development. The main gene candidate for Oia2 is Dcar1, as based on the finding of the 
inactivating, early nonsense mutation in DA rats. 
 
Previously, Mincle had been linked to RA in an indirect manner. Mincle is up-regulated 
in bone marrow derived mononuclear cells from RA patients, determined by micro array 
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(226). However, the up-regulation of Mincle may be a result rather than a causal factor in 
the precipitation of disease. A reduced number of BDCA-2 positive cells have been 
demonstrated in SLE and MS patients compared to healthy controls (227,228). However, 
since BDCA-2 is a marker for plasmacytoid DC (pDC), these reports only informs us that 
there are reduced numbers of pDC in the patients, and not of any involvement of BDCA-2 
in the diseases. pDC are major producers of interferon- which elevated in SLE patients, 
in this respect BDCA-2 triggering may be beneficial in SLE patients as BDCA-2 
triggering leads to reduced production of interferons (212,223). 
 
A report demonstrates that Dcir1 deficiency cause autoimmune disease, as Dcir1 knock-
out mice spontaneously develop sialadenitis (inflammation in salivary gland) and 
enthesistis (inflammation in tendon attachment site). These mice also spontaneously 
produce higher levels of autoantibodies like rheumatoid factor and autoantibodies specific 
for Sjögrens syndrome. Furthermore, the Dcir1 knock-out mice are more susceptible to 
collagen induced arthritis than wild-type mice. The Dcir1 knock-out mice have an 
expansion of dendritic cells, and the authors suggest that Dcir1 is involved in the 
maintenance of the DC population (229). 
 
Both the animal model OIA and genome scans points at a susceptibility locus for arthritis 
in APLEC (141,142). We therefore tested a panel of RA patients and healthy controls for 
SNPs within APLEC, which resulted in the finding of association of DCIR to RA anti-
CCP negative patients (paper IV). The SNPs used in the study was randomly chosen from 
reported SNPs in GenBank. At the start of the study, few SNPs were available, and most 
of them were located in intergenetic regions. Any association of arthritis to these SNPs 
would only indicate that a gene or genes were linked to disease. We found an association 
between RA in anti-CCP negative patients and SNP (rs1133104) and to a haplotype of 5 
SNPs mapping to DCIR. However only one marker (rs2024301) was within the coding 
sequence of DCIR, one in the 3’UTR (rs1133104) and the rest were located upstream of 
DCIR. These polymorphisms are unlikely to be responsible for the development of 
disease. Their association just points to DCIR as a candidate gene. We aim to verify the 
association of RA to APLEC using novel, more relevant SNPs covering APLEC in a 
Norwegian panel of RA patients. 
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Sverdrup reported that oil exposure is linked to increased risk of anti-CCP positive RA 
(103). In paper IV we found association of DCIR to anti-CCP negative RA. The 
difference in anti-CCP status may be a result of multiple pathogenic pathways. As 
demonstrated in a recent publication, the effect of the APLEC genes on arthritis 
phenotype vary between different arthritis models in the rat (230). Interestingly, the 
APLEC congenic rat strain (R17) showed elevated levels of autoantibodies in CIA 
compared to the more susceptible DA strain, despite lower arthritis severity score. It may 
be that RA/autoimmunity triggered by oil exposure in humans is linked to production of 
autoantibodies, whereas we in paper IV may have picked up subgroup of RA patients that 
are anti-CCP negative.  
 
Autoimmunity and occupational exposure to oil 
In 2003 an article series in the Norwegian newspaper “Dagbladet” identified a group of 
workers exposed for mineral oils through occupation who now experience various 
symptoms of autoimmune and inflammatory diseases. After an initial report of ~30 people 
exposed to mineral oil, more people with similar symptoms came forward, and now the 
group counts more than 150 people. Some of them have got the diagnosis MS, a few are 
diagnosed with RA, but most have got no diagnosis at all. The symptoms they experience 
range from different neurological and inflammatory autoimmune symptoms to cancer and 
hypersensitivity. The wide varieties of symptoms make it hard to find a link between their 
symptoms and work, and the individuals struggle with the acceptance that their conditions 
are work related.  
 
Because the workers in question have been exposed to different kinds of oil, it has been 
reasoned that it is not the oil in itself that triggers disease, but the additives in the oil. 
However, several reports of autoimmunity and autoimmune symptoms after 
administration of adjuvants exist, which have led to the proposal of human Adjuvant 
Disease (HAD) (91,93-99). Two publications confirmed occupational exposure to 
hydraulic oils and silica as risk factors for RA (103,104) and recently a cluster of SLE 
patients which had been exposed to an oil-waste reservoir was published (109). It is 
possible that the oil act as an adjuvant and that in susceptible individuals the oil triggers 
an unwanted immune response. The difference in symptoms may be explained by 
different composition of oils, additives in the oil and genetic background. In OIA the 
mineral oil triggers a pathogenic pathway where an APLEC gene is involved, and our 
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working hypothesis is that in certain cases of human RA and autoimmune diseases oil 
may function as an environmental stimulus that triggers a similar pathogenic pathway in 
which an APEC gene is playing a role. In parallel with the SNP typing of the Norwegian 
RA panel, the panel of oil exposed workers will also be typed to se whether any of SNPs 
in the APLEC genes show skewing compared to healthy controls. 
 
APLR and pathogenesis 
The OIA model has proven to be useful to find genetic risk factors for RA; however it 
may be even more valuable as a tool to determine the pathogenesis of disease. By 
generating an APLEC congenic strain, we are able to see differences in responses in DA 
versus R17 rats caused by APLEC genes after various stimuli. In paper V we show the 
effect of oil stimuli on the expression of APLEC genes and the consequences that had for 
cytokine expression. This work supports the hypothesis that Dcar1 is the most likely 
candidate for Oia2 although other APLEC genes cannot be ruled out as disease causing or 
contributing factors. Analysis of APLEC gene expression revealed that the receptors 
showed different expression in terms of fold up-regulation and pattern over time. This 
indicates that the genes are also regulated at the transcriptional level, and not only by 
influx of cells to the lymph nodes.  
 
Analysis of cytokine expression revealed a significant increase of Il17 expression in DA 
but not in R17 rats following oil injection. The fact that rats which develop arthritis 
express higher levels of Il17 transcripts is not surprising. IL-17 is an inflammatory 
cytokine produced by the Th17 subset and has been reported to be induced in EAE (231). 
It is also elevated in humans with a variety of other autoimmune diseases (232-235).  
 
Differentiation of the Th17 subset has over the last few years been extensively studied. 
Th17 cells are generated from CD4+ Treg precursors. In presence of TGF these cells 
develop into T regulatory cells promoting tolerance. However in presence of IL-6 and 
TGF, the precursors develop into IL-17 producing cells (236-238). The development of 
Th17 cells and IL-17 production can be amplified by presence of IL-1 and IL-23 
(239,240). IL-23 is also involved in maintaining IL-17 production (236). In our model we 
saw no difference in Il6 mRNA expression between DA and R17 rats, and the only other 
cytokine that showed a significant difference in expression between the two strains was 
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Il1b. It has been reported that development of the Th17 subset in mouse could be 
generated independently of IL-6, and that it is in fact IL-1 that plays the dominant role in 
the Th17development (241). Recently it has been demonstrated that early Th17 cell 
differentiation in the mouse is regulated by IL-1 signalling both in vivo and in vitro 
(242). Similarly, human Th17cells were induced by IL-1 and amplified by IL-6 
(243,244). Thus, it is possible that the elevated expression of Il17 in DA rats is directed 
by Il1b.  
 
The difference in Il17 mRNA expression between the APLEC congenic strain and the DA 
rat was striking. These two strains only differ in the APLEC, thus one or more of these 
genes are clearly involved in the generation of pathogenic IL-17 producing T cells in the 
DA rat. The presence of Il17 transcripts first presents at day 5p.i. in DA rats, indicating 
that the effect of APLEC gene(s) causing arthritis take place early in the induction phase. 
Prior to day 5p.i. there are only significant expression differences between DA and R17 
for Mincle and Dcir1 at day 2p.i. Therefore the gene candidates for Oia2 can be narrowed 
down to Mincle and Dcir1 based on mRNA expression and Dcar1 and Dcir2 based on 
sequence polymorphisms, with Dcar1 being the prime candidate due to the nonsense 
mutation, leaving the DA rat as a natural knock-out for this gene. In addition the most 
striking expression profile was that of Dcar1. After an early strong up-regulation, the 
expression drops, but remains at an elevated level until arthritis presents at day 14-15p.i.  
In squalene induced arthritis (SIA), a similar model to OIA, a pathogenic subset of T cells 
develops around day 5p.i. as determined by adoptive transfer experiments. T cells 
harvested form rats immunised with squalene can transfer arthritis to naïve rats if the T 
cells are harvested after day 5p.i. (245). Given the similarities between the two models, it 
is possible that a pathogenic T cell subset develops in the same period in OIA susceptible 
rats. As we see presence of Il17 from day 5 p.i., it is highly likely that this pathogenic 
subset is Th17 cells. 
 
Exactly how the APLEC receptors are involved is not understood and needs further 
investigation. However, it is tempting to speculate that the increased expression of Dcar1 
leads to a production of cytokines which inhibit the generation of Th17 cells in R17 rats, 
whereas the nonsense mutation prevent the synthesis of Dcar1 protein in the DA rat and 
leads to generation of Th17 cells.  
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It should be noted that we in our model only measured the mRNA expression. RNA 
expression does not always correlate with protein expression and there may be differences 
in the cytokines between DA and APLEC congenic rats at the protein level. We are 
currently investigating the difference in protein expression between DA and APLEC 
congenic rats for various cytokines. With a newly developed antibody against Dcar1 we 
are also able to verify the expression difference of Dcar1 between DA and congenic rats 
at the protein level. 
 
QTLs mapping to APLEC  
Rat chromosome 4 is dense in QTL for other experimental models for arthritis, like 
pristane induced arthritis (PIA), collagen induced arthritis (CIA), squalene induced 
arthritis and adjuvant induced arthritis (AIA) (189,246-250). A number of other 
experimental models such as the MS model experimental autoimmune encephalomyelitis 
(EAE), the diabetes models IDDM and NIDDM, (insulin dependent diabetes mellitus, 
non-insulin dependent diabetes mellitus) and experimental autoimmune uveoritinitis 
(EAU) also have QTLs located on rat chromosome 4, some of which have been mapped 
to span over APLEC (251-253). The EAE model is interesting in this regard, where a 
congenic interval gives down-modulating affect of arthritis and up-modulation of EAE 
(254).  
 
In the human, a genome scan in MS affected families revealed a peak with a lod 
(logarithm of odds) score on chromosome 12, corresponding to a nominal significance of 
5%, however the peak failed to be replicated in a second stage scan with higher stringency 
and lower number of affected families (255). The markers giving the peak cover APLEC, 
indicating a MS locus near or in APLEC. As mentioned in the introduction two meta-
analyses based on partly the same genome scans both reveals a locus linked to RA 
susceptibility, with cytogenic location that spans over the human APLEC (141,142). The 
fact that QTLs in several experimental models and QTLs found in human linkage and 
association studies maps to APLEC indicate that one or more of the APLRs may be 
involved in the pathogenesis of several autoimmune or inflammatory diseases. 
 
There are indications that several autoimmune diseases may share a common disease 
pathway. Originally identified as a gene regulating arthritis severity in the rat, Ncf1 is 
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linked to both CIA and EAE in the mouse (197). In the human, the gene PTPN22 have 
been associated with several autoimmune diseases; RA, type I diabetes, SLE and other 
inflammatory diseases 146,256-259), similarly CTLA4 have been associated with RA, 
Graves disease, type 1 diabetes, and other autoimmune diseases (173,260-262). For this 
reason we plan to test other autoimmune and inflammatory diseases for association to 
APLEC in parallel with the Norwegian RA panel. The patient material consists of patients 
with Type1 diabetes, atherosclerosis and inflammatory bowel disease. 
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Future perspectives 
Identifying risk factors to any autoimmune disease is important; however it is just a start. 
The ultimate goal is to develop better therapies; to slow down or stop the disease from 
progressing or even cure the disease. To develop better therapies we need to understand 
the pathogenesis of the disease. The association of RA to APLEC is thus only a small step 
forward, but the finding will instigate research on how the APLRs are involved in the 
development of disease.  
 
As mentioned in the discussion, SNP typing with novel SNPs to confirm association of 
APLEC to RA in a Norwegian patient material and to determine whether other 
autoimmune and inflammatory diseases are associated with APLEC is an ongoing work. 
Examining the APLEC genes with respect to expression and splice patterns in RA patients 
compared to healthy controls may give clues to how the receptors are involved in 
development of autoimmune reactions, and are ongoing projects in our laboratory. 
 
Future plans include studies of Aplr signalling, in both human and rat, hoping to delineate 
a pathogenic pathway. With new antibodies raised against rat Dcar1 and MCL we are 
better equipped to do functional studies. Biochemical analyses to reveal whether the 
APLEC receptors are homo- or heterodimers, as well as determining intracellular 
signalling pathways are planned. Examining the roles of the APLEC receptors by in vivo 
studies are intended. In particular, comparisons between DA and congenic strains and do 
in vivo blocking of the various receptors to see the effect of disease phenotype may give 
valuable clues to disease pathway. 
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Abstract 
The natural killer cell gene complex (NKC) encodes receptors belonging to the C-type lectin 
superfamily expressed primarily by NK cells and other leukocytes. In the rat the chromosomal 
region which starts with the Nkrp1a locus and ends with the Ly49i8 locus, is predicted to 
contain 67 group V C-type lectin superfamily genes, making it one of the largest congregation 
of paralogous genes in vertebrates. Based on physical proximity and phylogenetic 
relationships between these genes, the rat NKC can be divided into four major parts. We have 
previously reported the cDNA cloning of the majority of the genes belonging to the 
centromeric Nkrp1/Clr cluster and the two telomeric groups, the Klre1 - Klri2 and the Ly49 
clusters. Here we close the gap  between the Nkrp1/Clr and the Klre1 - Klri2 clusters by 
presenting the cDNA-cloning and expression patterns of eight genes spanning from Cd69 to 
Dectin1, including the novel Clec2m gene. The definition, organization and evolution of the 
rat NKC are discussed. 
 
Introduction  
In 1991 Yokoyama and co-workers showed that genes encoding the C-type lectin-like 
(CLEC) receptors NKR-P1 and Ly49 were genetically closely linked in the mouse and 
postulated the existence of a genetic region encoding functionally related C-type lectin 
superfamily (CLSF) members. As these receptors primarily were expressed by natural killer 
(NK) cells, it was named the NK cell gene complex (NKC) (Yokoyama et al. 1991). In the 
pursuit of identifying structural gene(s) associated with regulation of NK cell mediated 
alloreactivity in the rat, we subsequently identified the equivalent rat gene complex (Dissen et 
al. 1996). Remarkably, both in the mouse and the rat the genetic distance between the Nkrp1a
and the Ly49 genes was estimated to ~ 0.5 cM, based on analyses of recombinant inbred 
strains (Yokoyama et al. 1991) and parental to F1 backcrosses (Dissen et al. 1996), 
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respectively. Assuming normal crossing-over frequencies this would correspond to a physical 
distance of less than one Mb. However, the first physical map of the NKC, based on pulsed 
field gel electrophoresis, indicated the region to be much larger (Dissen et al. 1996). In the rat 
other CLSF genes were rapidly mapped to the intervening region (Berg et al. 1998a), (Berg et 
al. 1998b), (Dissen et al. 1997), followed by still more genes in the mouse and, with the 
identification of a human NKC, in the human (Renedo et al. 1997), (Suto et al. 1997), 
(Hamann et al. 1997), (Colonna et al. 2000), (Sobanov et al. 2001), (Boles et al. 1999), 
(Plougastel et al. 2001). The releases of the sequences amassed by the international genome 
projects finally exposed the real size of this gene complex in different species. Thus, aided by 
the Rat Genome project, we could report that the genetic region spanning from the most 
centromeric Nkrp1 to the most telomeric Ly49 gene covered 3.3 Mb, with a predicted content 
of 67 CLSF genes (Nylenna et al. 2005a). However, although the conservation of sequence 
features among the many intraspecific paralogs and interspecific orthologs has greatly 
facilitated prediction of novel CLSF genes, in silico prediction is error-prone and 
uninformative as to whether the predicted genes are expressed.  
 
Functional traits such as resistance to cytomegalovirus (rev. in (Webb et al. 2002) and fungal 
infection (rev. in(Sun and Zhao 2007) and association with celiac disease have been mapped 
to discrete genes in the NKC (Hue et al. 2004), and association to experimentally induced 
arthritis was mapped to the neighbouring gene complex, APLEC, also encoding CLSF 
receptors (Flornes et al. 2004), (Lorentzen et al. 2007). For other quantitative trait loci (QTL) 
mapped to this chromosomal region, including loci controlling experimentally induced 
inflammatory responses in the rat, the associated structural genes await identification. An 
accurate and complete inventory of the genetic content of this genetic region would represent 
a useful tool in their ultimate identification, and thus of importance for studying pathogenetic 
 4
mechanisms behind the human inflammatory and autoimmune diseases. We have previously 
described the cDNA cloning of the genes constituting the Klre1 - Klri2 cluster (Berg et al. 
1998a), (Berg et al. 1998b), (Dissen et al. 1997),(Saether et al. 2005;Westgaard et al. 2003) 
and, barring pseudogenes, most of the genes belonging to the Ly49 gene cluster (Naper et al. 
2002), (Nylenna et al. 2005b). Together the two clusters make up the telomeric part of the rat 
NKC. From the centromeric end of the complex we recently reported the cDNA cloning of 
the Nkrp1 genes and most of the Clr genes (Kveberg et al. 2009), leaving a gap between the 
most distal Clr gene and the Lox1 (Olr1) gene, previously reported by others (Nagase et al. 
1998) and situated immediately centromeric to the Klre1 - Klri2 cluster. Here we close this 
gap by presenting the cDNA cloning and expression patterns of eight genes spanning from 
Cd69 to Dectin1, including a novel gene which we have called Clec2m. We also include 
expression analyses of the Nkrp1 and Clr genes and present the genomic organization of the 
67 predicted group V CLSF localized in the rat NKC.  
 
Materials and Methods 
cDNA cloning 
As the genes reported here were cDNA cloned  before the availability of the rat genome 
sequence, they were identified as described in (Flornes et al. 2004) by searching 1) the 
GenBank rat Trace archive and the EST database for sequences homologous to the published 
mouse and human receptors, using the NCBI BLAST program, 2) performing pairwise 
BLAST on recently released partially or fully sequenced rat BAC clones. Gene specific 
(nested) primers in the 5- and 3-untranslated regions (UTRs) were generated from the 
predicted sequences (primers shown in Supplemental Table 1). The 3- UTR of Clec12a could 
not be identified and this gene was therefore cDNA cloned using RACE with nested 3’ 
primers from the GeneRacerTM kit (Invitrogen.com).  
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RNA from mouse and rat lymph node, bone marrow or testis were isolated with Dynabeads 
mRNA Direct kit (Invitrogen) and first strand cDNA synthesis was carried out with M-MLV 
reverse transcriptase RNase H (Promega) using 1 g total RNA in a 20-l reaction volume. 
PCR were performed on first strand cDNA using gene specific primers and PfuTurbo DNA 
polymerase (Stratagene) and the products were cloned into pCR2.1-TOPO vector 
(Invitrogen). For every gene three independent clones were sequenced. The sequences were 
analyzed using software supplied by the Norwegian EMBNet node at the Biotechnology 
Centre in Oslo, Norway. 
 
Quantitative PCR 
A panel of RNA from purified cells and tissues from PVG rats was prepared previously 
(Dissen et al. 1997). Briefly, cells and tissues were extracted by lysis in isothiocyanate (Gibco 
BRL) followed by ultracentrifugation on a cesium chloride (Gibco BRL) gradient and 
phenol/chloroform extractions. Dendritic cells were isolated by spontaneous migration from 
split ear-halves floating on RPMI for 48 hours, testis were dissected from rats at day 4 and 
week 7,5 and 15. RNA from dendritic cells and testis were isolated with RNeasy (Qiagen) and 
first strand cDNA synthesis for all samples were carried with Superscript II reverse 
transcriptase (Invitrogen) and random hexamers using 1μg total RNA in a 30 μl reaction. 
Amplification was performed on an Applied Biosystem 7900HT Fast Real Time PCR system 
(PerkinElmer) using the 5’nuclease assay and qPCR SuperMix with Rox (Invitrogen). 
Analyses were done with the SDS2.1 software (Applied Biosystems, PerkinElmer). Primers 
and probes were designed using PrimerExpress 3.0 (Applied Biosystems, PerkinElmer) and 
purchased from Eurofins MWG Operon (Ebersberg, Germany). Individual samples were run 
in triplicate, and the relative quantity of RNA for each target was normalised to RNA from 
the reference gene plasma membrane calcium ATPase 4 (PMCA4). 
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Bioinformatics 
Sequence similarity searches were performed with BLAST programs, running on the NCBI or 
Ensembl websites. The phylograms were constructed with NJ plot based on alignments with 
the ClustalX program, with the pileup program in the GCG package (Accelrys Inc., San 
Diego, CA), and Bayesian inference methods (MrBayes – http://mrbayes.csit.fsu.edu)  
 
 
Results and discussion 
Sequences and expression patterns  
Eight genes spanning the gap between the Nkrp1/Clr genes and the Lox1 locus were cDNA 
cloned. In Fig. 1 the predicted amino acid sequences are presented together with their mouse 
and human counterparts, with closest sequence similarity (Fig. 2) and conserved 
chromosomal positions and orientation between the three species as orthology criteria. 
Cd69 and Clec2m. Whereas the majority of class V CLSF genes consist of six coding exons,
Cd69 and Clec2m have only five (Fig.1). Rat Cd69 shows relatively high expression levels , 
as measured by RT-PCR, in dendritic cells derived from skin (sDC), peritoneal macrophages 
(pM) and resting B and T cells as well as ConA activated lymphocytes (Fig. 3). The 
expression in resting lymphocytes is noteworthy. Cd69 was first cloned in the human (Ziegler 
et al. 1993), where it originally was reported as expressed primarily on activated lymphocytes 
and on NK cells, neutrophils and platelets. The CD69 receptor has consequently been widely 
used as an in vivo as a marker for leukocyte activation and inflammatory responses. It has 
been extensively studied in the human and the mouse, where in vitro studies originally 
indicated proinflammatory function, but where more recent in vivo results indicate that it may 
act as a regulatory molecule, modulating inflammatory responses (rev. in (Sancho et al. 
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2005)). Clec2m has to our knowledge not previously been cDNA cloned. Hao et al. (Hao et al. 
2006) labeled the in silico predicted rat and mouse gene Clec15a and Clec15ap, respectively, 
with the mouse gene predicted to be a pseudogene. We have cDNA cloned full-length 
versions of the gene both in the rat and the mouse (Fig.1), but were unable to identify it in the 
human. As the term Clec15a is an established synonym for Klrg1 (Mafa), we propose the 
name Clec2m, denoting close kinship to the Clr (Clec2d) genes and high expression in 
macrophages (see below). The gene shows highest expression levels in sDC and pM, and 
among tissues bone marrow and testis (Fig. 3).  
Clec12a (Micl) and Clec12b   Clec12a possesses a single immunoreceptor tyrosine-based 
inhibition motif (ITIM) sequence (IxYxxL) in the cytoplasmic tail. Rat Clec12b contains the 
ITIM-like sequence AxYxxL, whereas mouse and human Clec12b both have the consensus 
ITIM VxYxxL (Fig. 1). For CLEC12A the inhibitory function suggested by the ITIM has 
been demonstrated both in the human, where it was first identified as myeloid inhibitory C-
type lectin-like receptor (MICL) (Marshall et al. 2004), and later in the mouse (rev. in 
(Huysamen and Brown 2009)).  In the human and the mouse (Pyz et al. 2008) Clec12a is 
expressed predominantly on DC, macrophages and granulocytes, and down-regulated 
following stimulation with select TLR (toll-like receptors) ligands. In the rat, the highest 
expression levels of Clec12a were found in sDC and pM, and among tissues in bone 
marrow and brain. Less is known about the closely related Clec12b (rev. in (Huysamen and 
Brown 2009). Its expression profile in the rat is distinct from that of Clec12a, with moderate 
expression levels in sDC and neutrophils, no detectable expression in pM, and with strong 
expression in the testis (Fig. 3).   
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Clec1b, Clec9a and Dectin1 These receptors share the atypical immunoreceptor tyrosine-
based activation motif (ITAM) D/ExYxxL in their cytoplasmic tail (Fig.1). In the human and 
the mouse all three have been shown to recruit and mediate activation signals via spleen 
tyrosine kinase (Syk) (Rogers et al. 2005), (Fuller et al. 2007), (Huysamen et al. 2008). 
Clec1b, first identified in the human and named CLEC-2 by Colonna et al. (Colonna et al. 
2000), is expressed on various cell types including megakaryocytes and platelets, where it 
triggers platelet activation and aggregation (Suzuki-Inoue et al. 2006). Various exogenous and 
one endogenous ligand, the sialoglycoprotein podoplanin, have been identified (Suzuki-Inoue 
et al. 2007). In the rat, Clec1b expression levels are moderate in neutrophils, low in 
lymphocytes, undetectable in sDC and pM and high in spleen and liver (Fig.3). Clec9a has 
recently been identified both in the human and the mouse as an activating receptor 
(Huysamen et al. 2008), (Caminschi et al. 2008), expressed primarily by a subset of 
monocytes and the rare CD141+ subset of DC (Huysamen et al. 2008). In the rat, it shows 
high expression in the spleen, moderate to low expression levels of several other tissues and 
cell types, but no detectable expression in sDC or CD4+ T cells (Fig.3). Whereas the 
physiological roles of Clec1b and Clec9a remain unknown, much insight has been gained 
about roles of Dendritic cell-associated C-type lectin 1 or Dectin1. It was first identified in the 
mouse (Ariizumi et al. 2000) and has been shown both in the mouse and in the human to 
function as the main leukocyte -glucan binding receptor, with a major role in antifungal 
immunity (Brown 2006), (rev. in (Sun and Zhao 2007)). In the mouse Dectin1 is most 
strongly expressed on monocytes, macrophages, neutrophils and microglia, weakly on a T cell 
subset, and in the human also on B cells, mast cells and eosinophils (Brown 2006). In the rat, 
Dectin1 is expressed in all tissues and cell types tested (except the RNK16 cell line), with 
particularly strong expression in sDC, pM, bone marrow and the thymus (Fig.3). 
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Clec1a Finally, although the human Clec1a receptor was first published ten years ago, under 
the name CLEC-1 (Colonna et al. 2000), little is known about its functional properties and 
roles. In the  human, the cytoplasmic tail contains one tyrosine residue close to the N-
terminus. This is also present in the mouse and the rat sequences, which have an additional 
tyrosine residue forming the pattern YxxTx13YxxT(Fig. 1). Whether the tyrosines are subject 
to phosphorylation is not known. A notable sequence feature of Clec1 is the two cysteines 
immediately preceding the cysteines predicted to form the disulphide bond labeled 2 in fig. 1. 
This is a characteristic shared with the Ly49 receptors, where the two extra cysteines form an 
additional SS-bond between the 1 chain and the last  chain of the lectin domain. In the rat 
Clec1a is expressed in all cell types and tissues tested, with strongest expression in ConA-
stimulated blasts, the spleen and the kidneys.  
 
Comments on expression patterns 
The presence of ITIM motifs in Clec12a (and possibly Clec12b) and (atypical) ITAM motifs 
in Clec1b and Clec9a suggests inhibitory and activating functions, as shown for the human 
and mouse orthologs. The occurrence of closely related receptors with opposite signaling 
properties is suggestive of opposing pairs, but this seems contradicted by their widely 
different expression profiles (Fig. 3). In Fig. 3 we have also included expression analyses of 
the Clr and the Nkrp1 genes, as this information has not previously been published in the rat 
and is therefore needed for complete comparison of the expression programs of the rat NKC 
genes. The pattern of strong NK cell expression exhibited by NKR-P1A, -B and -F  receptors 
is the rule for the majority of the rat NKC receptors previously reported. In contrast, most of 
the genes reported here, as well as most of the Clr genes, show modest to low or no 
expression in NK cells, demonstrating a genetic content beyond the original definition of this 
large congregation of genes as an NK cell gene complex. 
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Phylogenetic analyses 
A striking feature of the eight receptors reported is the wide range of sequence divergences 
between the rat, mouse and human orthologs (Fig.2). The most extreme examples are Clec1a, 
which is highly conserved, and Clec12a, which is extensively changed between the three                      
species  (Figs 1 and 2). For Clec1a the rat and mouse protein per cent identity is 95.5 and the 
rodent versus human identities 71.3/69.4 (human-rat/human-mouse). For Clec12a the 
corresponding figures are 73.3 and 47.7/50.6. The dissimilarities between the three Clec12a 
sequences suggest positive selection, a notion further strengthened by Ka/Ks analyses of the 
cDNA sequences. Ka/Ks analysis compares the rate of non-synonymous to synonymous 
substitutions, with a higher value indicating possible positive selection. For Clec1a the mouse 
versus rat Ka/Ks ratio is 0.10, and for Clec12a 1.00. Splitting the Clec12a sequences into 
exons 1-3, encoding the cytoplasmic tail/transmembrane/neck domains, and exons 3 – 6, 
encoding the the lectin domain, i.e. the presumed ligand binding part of the receptor, gives 
Ka/Ks values of 0.57 and 1.42, respectively. The ligand of these receptors are unknown, but 
the analysis suggests that the Clec1a ligand is phylogenetically conserved, whereas the 
Clec12a receptors may be chasing a more rapidly evolving ligand.   
 
Phylogenetic analyses indicate that CD69 and Clec2m belong to a different subfamily than 
the other six receptors (Fig. 2). On inclusion of the other CLSF receptors encoded by the rat 
NKC, they exhibit closest sequence similarity with the Clr subfamily (Fig. 4). Although 
sensitive to gap parameters and not significant according to bootstrap analyses, the 
association seems reasonable considering the physical localization of Cd69 and Clec2m next 
to the Clr genes (Fig. 5) combined with the fact that they consist of only five coding exons, 
lacking a separate exon encoding the external membrane-proximal stalk. This is a property 
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they share with the Clr genes, and contrasts with all the other NKC CLSF genes, which 
generally consist of six coding exons (apart from Lox1 which have eight coding exons).  
 
As for the other six genes, the Clec12 and Clec1 genes tended to cluster together (Fig. 2). The 
shape of the tree is, however, highly sensitive to gap parameters and to inclusion of other 
NKC genes (Fig. 4). The tree shape in Fig. 2 is similar to that reported by Hao et al, except for 
Clec9a, which was assigned to an entirely different clade of CLSF genes (Hao et al. 2006). 
Arguments in favor of including Clec9a in the Clec12 – Lox1 clade is the sharing of 
chromosomal localization and sequence features such as the atypical ITAM motif. 
Furthermore, a conserved feature of the NKC encoded CLSF receptors is the Cx10C loop of 
amino acids clamped by an SS-bridge between the flanking cysteines labeled 1 in Fig. 1. In 
front of these do Clec1a and –b, Clec12a and - b and Clec9a have two additional cysteines, 
the first encoded by a codon near the end of exon 3 (Fig. 1) and restricted to these receptors , 
whereas the second, encoded by the third codon in exon 4  (Fig. 1) is also present in CD94, 
Klrk1, the Nkg2 and the Klri receptors. The atypical ITAM motif and the two extra cysteines 
are likely to represent derived (apomorphic) rather than ancestral (plesiomorphic) states, so 
that the assigning of Clec9a to a different clade would implicate convergent evolution or 
sequence transfer through gene conversion. The simpler explanation is that their shared 
presence stems from phylogenetic kinship. Whether the extra cysteines are involved in inter- 
or intrachain disulphide bonding is not known.  
 
The organization of genes in the rat NKC 
The phylogenetic tree shown in Fig. 4 includes group II and group V CLSF members 
localized on rat chromosome 4 (for simplicity only eight Ly49 genes are shown, as all 34 
cluster together in a single clade). In addition to the genes depicted in Fig.5 the tree includes 
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Mafa1 (Klrg1), Mdl1 (Clec5a) and the seven genes grouped together in the Aplec cluster. The 
tree is seen to consist of six major branches. The exact branching is highly sensitive to gap 
parameters, but apart from the placement of Clec9a discussed above is identical to the tree 
presented by Hao et al (Hao et al. 2006) with respect to major branches. The interesting 
feature of the tree is that the gene content of the major branches correlates exactly with the 
chromosomal clustering of the genes (apart from Mafa1 and Mdl1). In addition to supporting 
the soundness of the tree, the observation indicates that this large congregation of paralogous 
genes has evolved by local gene duplications without major reshufflings. At the local level 
chromosomal inversion events have occurred, as evidenced by the changes in gene 
orientations, as well as segmental duplications involving more than one gene in the case of the 
Ly49 gene cluster, as previously discussed (Nylenna et al. 2005b). A notable feature is the 
conservation of orientation of the 41 moste telomeric genes of the complex, from Klrk1 to 
Ly49i8. The evolutionary events leading to the gene arrangement of the Nkrp1/Clr cluster 
seem particularly complex. In addition to shifting gene orientations, the cluster consist of two 
separate blocks containing Nkrp1 genes with opposite signaling function next to series of Clr
genes with incongruent patterns of topographical versus sequence neighbourness.  
 
The demarcation of the NKC 
The chromosomal region starting with Nkrp1a and ending with Ly49i8 contains almost all 
known group V CLSF genes in the rat. Exceptions are Cd72, localized on chromosome 5, and 
Klrg1 (Mafa1), Mdl1 (Clec5a) and Clec2l, all three on rat chromosome 4, at distances 7, 97 
and 99 Mb centromeric to Nkrp1a, respectively. Furthermore, the region contains nothing but 
group V CLSF genes, with Gabarapl1 (Gamma-aminobutyric acid receptor-associated 
protein-like 1) as the single known exception. Although heterogeneous in gene content it 
displays conserved gene organization and persistence of orthologous gene lineages across 
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four major mammalian orders, as described by Hao et al. (Hao et al. 2006). These authors also 
included in the NKC the Mincle – Dcir gene cluster (Fig. 5) which in all four orders occupy a 
chromosomal region close to, but clearly separate from the Nkrp1a - Ly49i8 region. When we 
first described the genetic region containing the Mincle – Dcir gene cluster, which we named 
the antigen-presenting cell lectin-like receptor gene complex (APLEC), we presented 
arguments for and against including these genes in the NKC. Counterarguments were 1) The 
evolutionary distance between the two groups of genes. Whereas the APLEC genes are 
classified as group II CLSF  (http://www.imperial.ac.uk/research/animallectins/), with 
conserved amino acid residues involved in calcium dependent saccharide binding (Weis et al. 
1991),  the group V CLSF have lost these amino acid motifs (Weis et al. 1998). 2) The 
distance separating the APLEC genes from the NKC. In the mouse and the rat it is 5 - 6 Mb, 
in the human, cow, horse and dog only ~ 1.5 Mb. In all these species the intervening region is 
packed with non-CLSF genes, which would be included in the NKC if defined as 
encompassing the APLEC, with loss of communicative precision and a potential source of 
confusion in the future mapping of functional traits to this chromosomal region. Even when 
narrowly defined the NKC represent one of the largest congregation of paralogous genes 
known in vertebrates.  
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Supplementary Table 1: Primers used for cDNA cloning.  
 
Only the innermost pair of nested primers. * Clec12a was cloned using nested 3’ primers from 
GeneRacerTM kit (Invitrogen.com).  
 
Supplementary Table2: Primers and probes used for qPCR. 
Gene  Forward Reverse Probe (5’-FAM, 3’-TAMRA) 
Nkrp1a TCAGTGTGTATCACCTCCATCTCTTC TTCAAAGCCAACCTGTGTGAAC CCCAGATGCCTGTCGGTGCCC 
Nkrp1b GAGCCACCTCCATCTCTTTCC CAAGCACAGCCGAGTTTCAG CCCGCGCTGGCATCGATTG 
Nkrp1f CATTCCCATCTCTCTCCACAGAT CAGCCAAGTTTCAGAGCCAAA CTTGTCGGTGCCCACACTGGCA 
Nrkp1g TTTGGAAGTGGATGAATGGTTCT GAGATGAGGGCACAGCTGTTT ACGCATCACCGGCAAGAACGAAG 
Clr2 GATCGGTCTGCACAGAGAGTCA CGATGGGAACCAAATTGTTATATG CATCACAGCCTTGGAAGTGGACAGACAAC 
Clr4 TAACTGGACATTCAGCCAGGACTT CCCTTTGTGTCTCTTTAGGAAATTCA AGGCCGAGCTAGCACGATTTGACACC 
Clr6 GCCAGACCCTCTGTAAGGAACA CGGACTCCCTTTGTATCTCCTTAA AGGCCGAGCTAGCACGATTTGACACC 
Clr7 GAGAAACAGGTGAAATGCTCCAT TGAGGACTAGGATCACTGCATAACA TCTCAGAATCTTCTCCCCTGAATCTCCTGC 
Clr10 ACGTGGGAAACTGGACATTCA TCCTCCAGGCTGTCAAACAGA CCTCGTGCATGGCATTAGATTCCCATC 
Clr11 GGAGGGAGAAATGGGTAAAATGT CCATAGCAGCAGTAAAGCTTAGCA AAATGTCTCAGAATCGTCTCCCCCGAA 
CD69 CGTTTCTCAGCCCAATCCA GCTGTTATTGATTCGGAAAAGGA TGTTTCAGTCCACCAGCATATCGCTTCA 
Clec2m GACCGAAAGCTCCCTCAGACT AACACCAATTACCAGGATCCAAA TCTCAGTCAAGCCACCACCGGTTAACA 
Clec12a AGCCAGAAGTCTGACAAATGTGGG AAGATGCATCCTAAGGCCACCACT AGTACCTTCTGCTGGTTCCTATTCACAACA 
Clec12b TGGCTGTGGGAGGATGGT GATCCATTGAAACTGGCAAGCT CGTTGCCCCCTCCAACCCTATTTAATG 
Clec2 AAGCCCCGGAAACAAGCT AGCCCCATGGTTGAGATCAG TCAGCTGAGCCTGCCTCTTCTTGGTG 
Clec9a CCATTTTCTTGGGCATCAAGTT TCCTGTCGGATGAGCCTTTC TCCCAGGTGTCCTCTCTTGTAATGGAGCA 
Clec1a TGTATTCTGGAACATCCACTGTCA TGGGCGCCAAACTGAAGA ACGAGCAGAGCCCAGGCACTCAGA 
Dectin1 CCTCCAAGGCATCCCAAA TGGCATGCATGATCCAATTG ACAGGCGTCTTTTCTGGACCTTGCC 
Lox1 CCTATCTTTAGATGCCCAGTTACTAC CCGATGTAATCCCATCCAAAA TCTTACAAGCAACTTCCCATTCCACCTCC 
Pmca4 TGGCGTTGCCCATCGT GGCCTACTCTGTAAAGAAAATGATGA CACAGGCGTCCAAGTGCCGGAC 
 
Gene  Forward Reverse 
rClr2 CATGTCTCCCTTGAATCCTAGGGAC GTAGATAGCATGTTCTGTGTTCCTCGTG 
rClr4 GAGATCTAACCATGTCTCCCTTGAATCCT GACAAACTCTCTACCCAGGACACAAAAC 
rClr6 GATCTAACCATGCCTCCCTTGAATCCT GGACAAACTCTCTACCCAGAACACGAA 
rClr7 CCAGGATTAGACAAAATTCCCTGTC GTTAATGAGGCAGCTACTGTAGAGA 
rClr10 TCTTCCTCTCAGCTCAGACATGGGT TCTCACGCATGCTTTGGCACATTCC 
rClr11 CCTCCTGTAGCAGAACCCAGCTT GGAAAGAGTAGCACCCATAGATAGCAGA 
rCD69 AGGGCACACCATAGACCACT TGCTATGGCACAGTCACCTATACC 
rClec2m CTCAACCTCTGTAGTCACTGAAGCG AGTTTAATTGCTGGCTTCTTAGTAAC 
rClec12a GACGGTTTCTGGAGCTTTCTCTGAAT * 
rClec12b TGGGCCTGAAGAAATTGCAACA GCTTCCTCCTTTCTTGCATGGGT 
rClec1b GAGCTTTGACCTCCTGGCAGTTCAAG TTCTCTGACATCCTGCCGGTCCTT 
rClec9a GTGTTGGGCTCCTATGTTGAC TGCTCTCTGACCTCTTTCGAAC 
rClec1a TCTCACCGGCATTTCTGCAGGAATC CCTTCACGTTGCCCTCCCTTGACA 
rDectin-1 ACATTCAAGTGCTCTGCCTACGTAGA ACACGCATTCCACCTTTACACTCTC 
mClec2m CCTTTCCGCTTAAGAATTTTCTCAATCT TACACATCACAGACAAAACGAGACACTG 
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Figure legends 
Figure 1. Amino acid sequence alignments of the CLSF receptors.  
r – rat, m – mouse, h – human. Dashes (-) means identity with top sequence. Points (.) 
indicate gaps. Ex1, Ex2, etc. on top of alignment show start site of corresponding exons. 
Transmembrane regions underlined. ITAMs and ITIMs indicated. Potential N-glycosylation 
sites boxed. Membrane external cysteines highlighted in yellow. Numbers connected with 
black lines on top of the CD69 and Dectin-1 sequences indicate SS-bonds as demonstrated for 
crystal structures of human CD69 and mouse Dectin-1 (http://www.ncbi.nlm.nih.gov/ 
Genbank/). For the other genes the corresponding cysteines are similarly numbered. X above 
cysteines in Clec1a indicates probable extra disulphide bridge, which in addition to the bridge 
between the cysteines labelled 2, links the first  helix with the last  strand of the CTL 
domain. Genbank accession numbers: rat CD69 - GU357488, rat Clec2m - GU357487, mouse 
Clec2m - GU553093, rat Clec12a - GU357484, rat Clec12b - GU357483, rat Clec1b - 
GU357482 rat Clec9a - GU357486, rat Clec1a - GU357481, rat Dectin-1 - GU357485   
 
Figure 2.  Dendrogram of the novel receptors (plus Lox1) and their human and mouse 
orthologs (based on amino acid sequences). Numbers indicate bootstrap values (1000 
reiterations) and Bayesian clade credibility values. Values shown only for branching points 
with bootstrap values > 900 or credibility values > 90. 
 
Figure 3. Gene expression as measured by quantitative PCR.  
The expressions of genes were calculated as the ratio of copy number of target gene to the 
copy number of endogenous reference gene, PMCA4. Thresholds for intermediate and high 
expression were set to 1/100 and 1 relative to PMCA4. Not detected: no PCR product 
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detected after 40 cycles. DC - dendritic cells, PM - peritoneal macrophages, RNK16 - NK cell 
line, LAK - Il2-stimulated NK cells. Similar results were obtained using the HPRT1 gene 
(Hypoxanthine guanine phosphoribosyl transferase 1) as endogenous reference gene. 
 
Figure 4. Dendrogram based on deduced protein sequences of all the CLSF genes encoded by 
the rat NKC (only eight of the predicted 34 Ly49 receptors shown). Also included are Mafa-
1/Klrg-1 and Mdl-1/Clec5a, plus the seven predicted functional Aplec genes. Vertical black 
lines indicate major branches of the NKC receptors. The genes containing five coding exons 
indicated with 5 ex. Only bootstrap values > 900 from 1000 reiterations shown. 
 
Figure 5. Map of the rat NKC. Arrows indicate gene orientation. Numbers below the line 
indicate distance from the starting point (the Nkrp1 gene at 165.637 Mb according to the 
current release of the rat genome). The four major clusters indicated with colour codes: green: 
Nkrp1/Clr gene cluster (including Cd69 and Clec2m), magenta: Clec12a – Lox1 cluster, red: 
Klre1 – Klri2 cluster, blue: Ly49 cluster. The topography of the chromosomal map with 
respect to major clusters is seen to be congruent with the major branches of the phylogenetic 
tree in Fig. 4.  
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